


Supplementary Figure 1 Necroptosis-related gene and long noncoding RNA expression. A: Heatmap of the expression of 67 necroptosis-related genes; B: Heatmap of the expression of 1249 necroptosis-related long noncoding RNAs (lncRNAs); C: Volcano plot of the differentially expressed necroptosis-related lncRNAs; D: The network connecting the necroptosis-related genes and lncRNAs (correlation coefficient > 0.4 and $p < 0.001$). FC: Fold change.


A

	<i>p</i> value	Hazard ratio
AC008760.1	<0.001	2.157(1.401-3.320)
AC007038.2	0.009	1.531(1.112-2.109)
AC073957.3	0.026	1.450(1.046-2.010)
AP001469.3	0.032	1.671(1.045-2.673)
AC079654.1	0.023	1.513(1.060-2.161)
AL161729.4	0.007	1.580(1.134-2.201)
LINC01876	0.031	1.505(1.038-2.182)
AC092535.4	0.016	1.392(1.064-1.820)
SNHG16	0.035	0.596(0.369-0.964)
AL354993.2	0.027	1.484(1.047-2.105)
AC007128.1	0.043	1.599(1.016-2.516)
AC011462.4	0.008	1.790(1.162-2.759)
AC016394.1	0.043	1.415(1.011-1.981)
AC008341.2	0.009	1.558(1.117-2.173)
AP006621.2	0.006	1.453(1.111-1.902)
LINC02381	0.014	1.619(1.101-2.381)
LINC01138	0.002	2.331(1.378-3.953)
AC099850.3	0.048	0.747(0.559-0.998)
AC010973.2	<0.001	2.285(1.431-3.649)
AC018653.3	0.042	1.464(1.014-2.113)
AC087741.1	0.042	1.596(1.017-2.504)
AC084033.3	0.023	1.772(1.084-2.896)
LINC38-AS1	0.011	1.541(1.104-2.152)
MIR4435-2HG	0.018	1.766(1.103-2.827)
ZKSCAN2-DT	0.006	1.716(1.169-2.519)
AC245100.7	<0.001	2.084(1.397-3.110)
AP001628.1	0.037	1.426(1.022-1.991)
AC078778.1	0.016	1.514(1.081-2.120)
AL137782.1	0.016	0.384(0.177-0.835)




B


	<i>p</i> value	Hazard ratio
AP001469.3	0.132	1.485(0.888-2.484)
AC007128.1	0.062	1.648(0.976-2.784)
LINC02381	0.095	1.477(0.934-2.337)
AC099850.3	0.085	0.747(0.536-1.041)
AC010973.2	0.003	2.172(1.300-3.629)
MIR4435-2HG	0.010	2.110(1.192-3.736)
AC245100.7	0.030	1.602(1.046-2.455)
AL137782.1	0.003	0.324(0.153-0.688)




C




Supplementary Figure 2 Construction of a signature including 8 necroptosis-related long noncoding RNAs that was associated with overall survival in colorectal cancer. A: Necroptosis-related long noncoding RNAs (lncRNAs) significantly correlated with overall survival by uni-Cox regression analysis ($p < 0.05$); B: Multivariate Cox regression analysis results showing that the 8 necroptosis-related lncRNAs could be used to evaluate colorectal cancer prognosis; C: Sankey diagram of the necroptosis-related genes and lncRNAs. LncRNAs: Long noncoding RNAs.




Supplementary Figure 3 Principal component analysis was used to compare the efficiencies of models constructed based on different gene sets in stratifying the overall survival of colorectal cancer patients. A: Models constructed based on all genes; B: Models constructed based on differentially expressed long noncoding RNAs (lncRNAs); C: Models constructed based on necroptosis-related genes; D: Models constructed based on all necroptosis-related lncRNAs; E: Models constructed based on our signature lncRNAs. lncRNAs: Long noncodingRNAs.




Supplementary Figure 4 The prognostic value of the necroptosis-related long noncoding RNAs signature for colorectal cancer patients stratified by clinicopathological characteristics. A: The differences in the risk score (RS) for different T stages; B: The differences in the RS for different N stages; C: The differences in the RS for different M stages; D: The differences in the RS for different total stages.




Supplementary Figure 5 The Univariate Cox and Multivariate Cox regression analyses to estimate the multiple clinical factors and the rickscore for overall survival and the 8 long noncoding RNA expression with the overall survival respectively in the clinical-colorectal cancer cohort. A and B: Univariate Cox regression analyses (A) and Multivariate Cox regression analyses (B) to estimate the multiple clinical factors and the rickscore for overall survival in the clinical-colorectal cancer (CRC) cohort; C to J: Survival analyses for patients with low or high of the 8 long noncoding RNA expression in the clinical-CRC cohort with significantly different survival result of the Kaplan–Meier method.



Supplementary Figure 6 Correlations between long noncoding RNA expression and clinicopathological characteristics, such as age and gender, in colorectal cancer. A: The 8 long noncoding RNA (lncRNA) expression in the distinct age group in the The Cancer Genome Atlas (TCGA)-colorectal cancer (CRC) cohort; B: The 8 lncRNA expression in the distinct gender group in the TCGA-CRC cohort; C: The 8 lncRNA expression and riskscore distributed in the distinct age group in the Clinical-CRC cohort; D: The 8 lncRNA expression and riskscore distributed in the distinct gender group in the Clinical-CRC cohort. LncRNAs: Long noncodingRNAs.



Supplementary Figure 7 A-P The 16 immunotherapeutic anticancer drugs that showed lower half-maximal inhibitory concentration values in the high-risk group.



Supplementary Figure 8 The 22 chemotherapeutic or targeted drugs that showed lower half-maximal inhibitory concentration values in the high-risk group.

Supplementary Table 1 The Correlation coefficients between necroptosis-related genes and long noncoding RNAs

Cor filter = 0.4; *p* value filter = 0.001

Necroptosis-gene	LncRNA	Cor	<i>p</i> value	Regulation
MAPK8	AC07990	0.539733	4.96E-4	Positive
	7.1	966	4	e
ATRX	AC07990	0.535775	2.70E-4	Positive
	7.1	63	3	e
OTULIN	AC07990	0.594953	2.17E-5	Positive
	7.1	612	5	e
MAP3K7	AC07990	0.539163	6.34E-4	Positive
	7.1	062	4	e
CYLD	AC07990	0.432298	3.94E-2	Positive
	7.1	04	7	e
IPMK	AC07990	0.522066	8.01E-4	Positive
	7.1	004	1	e
BRAF	AC07990	0.585108	3.33E-5	Positive
	7.1	314	3	e
CFLAR	AC07990	0.449745	1.75E-2	Positive
	7.1	336	9	e
TSC1	AL03160	0.479303	8.57E-3	Positive
	0.1	167	4	e
MAPK8	AL03167	0.622384	6.75E-6	Positive
	0.1	22	2	e
ATRX	AL03167	0.751184	1.22E-1	Positive
	0.1	455	03	e
OTULIN	AL03167	0.759382	3.62E-1	Positive
	0.1	072	07	e
MAP3K7	AL03167	0.569441	7.11E-5	Positive
	0.1	453	0	e
BCL2L11	AL03167	0.489069	2.60E-3	Positive
	0.1	122	5	e

CYLD	AL03167	0.682102	1.46E-7	Positiv
	0.1	141	8	e
FADD	AL03167	-0.41262	1.23E-2	Negati
	0.1	1222	4	ve
IPMK	AL03167	0.607216	3.20E-5	Positiv
	0.1	924	8	e
KLF9	AL03167	0.458508	1.02E-3	Positiv
	0.1	912	0	e
BRAF	AL03167	0.794926	2.77E-1	Positiv
	0.1	451	24	e
CFLAR	AL03167	0.664243	3.56E-7	Positiv
	0.1	347	3	e
MAPK8	AP00233	0.662827	9.18E-7	Positiv
	6.2	422	3	e
ATRX	AP00233	0.674078	4.28E-7	Positiv
	6.2	721	6	e
OTULIN	AP00233	0.810032	1.27E-1	Positiv
	6.2	829	32	e
MAP3K7	AP00233	0.664349	3.32E-7	Positiv
	6.2	694	3	e
BCL2L11	AP00233	0.473008	7.70E-3	Positiv
	6.2	945	3	e
CYLD	AP00233	0.679284	1.09E-7	Positiv
	6.2	243	7	e
IPMK	AP00233	0.616524	1.88E-6	Positiv
	6.2	895	0	e
KLF9	AP00233	0.414734	6.76E-2	Positiv
	6.2	541	5	e
BRAF	AP00233	0.817248	7.13E-1	Positiv
	6.2	209	37	e
CFLAR	AP00233	0.664669	2.67E-7	Positiv

	6.2	872	3	e
OTULIN	AC00876	0.435434	1.52E-2	Positiv
	0.1	75	7	e
MAP3K7	AC00876	0.401135	2.96E-2	Positiv
	0.1	428	3	e
TSC1	AC00876	0.505195	6.26E-3	Positiv
	0.1	116	8	e
BRAF	AC00876	0.477637	1.54E-3	Positiv
	0.1	648	3	e
CFLAR	AC00876	0.499543	5.37E-3	Positiv
	0.1	217	7	e
MAPK8	AL16189	0.532578	1.04E-4	Positiv
	1.1	728	2	e
ATRX	AL16189	0.691819	1.16E-8	Positiv
	1.1	032	1	e
OTULIN	AL16189	0.685796	1.00E-7	Positiv
	1.1	462	9	e
MAP3K7	AL16189	0.655594	1.07E-7	Positiv
	1.1	522	0	e
TSC1	AL16189	0.400267	3.75E-2	Positiv
	1.1	032	3	e
CYLD	AL16189	0.523141	5.17E-4	Positiv
	1.1	718	1	e
IPMK	AL16189	0.556570	2.86E-4	Positiv
	1.1	625	7	e
BRAF	AL16189	0.658668	1.44E-7	Positiv
	1.1	276	1	e
CFLAR	AL16189	0.609099	1.15E-5	Positiv
	1.1	581	8	e
CFLAR	AL59254	0.537819	1.13E-4	Positiv
	6.1	127	3	e

SPATA2	AC12406	0.452419	7.41E-3	Positiv
	7.4	183	0	e
MAPK8	AC08722	0.458633	9.79E-3	Positiv
	2.1	064	1	e
ATRX	AC08722	0.526034	1.58E-4	Positiv
	2.1	205	1	e
OTULIN	AC08722	0.592458	7.91E-5	Positiv
	2.1	043	5	e
BCL2L11	AC08722	0.472679	8.63E-3	Positiv
	2.1	29	3	e
TSC1	AC08722	0.407020	5.89E-2	Positiv
	2.1	364	4	e
CYLD	AC08722	0.520243	1.68E-4	Positiv
	2.1	58	0	e
BRAF	AC08722	0.665465	1.57E-7	Positiv
	2.1	49	3	e
CFLAR	AC08722	0.601909	5.57E-5	Positiv
	2.1	598	7	e
MAPK8	AL51332	0.636892	1.31E-6	Positiv
	7.1	584	5	e
ATRX	AL51332	0.681315	2.56E-7	Positiv
	7.1	16	8	e
OTULIN	AL51332	0.779071	2.95E-1	Positiv
	7.1	934	16	e
MAP3K7	AL51332	0.613799	8.60E-6	Positiv
	7.1	517	0	e
BCL2L11	AL51332	0.504051	9.70E-3	Positiv
	7.1	38	8	e
CYLD	AL51332	0.676490	7.89E-7	Positiv
	7.1	9	7	e
IPMK	AL51332	0.547380	1.77E-4	Positiv

	7.1	648	5	e
KLF9	AL51332	0.475309	3.47E-3	Positiv
	7.1	176	3	e
BRAF	AL51332	0.783941	1.19E-1	Positiv
	7.1	884	18	e
CFLAR	AL51332	0.755079	2.68E-1	Positiv
	7.1	562	05	e
MAPK8	AC01083	0.640461	1.49E-6	Positiv
	4.3	278	6	e
ATRX	AC01083	0.780298	7.48E-1	Positiv
	4.3	067	17	e
OTULIN	AC01083	0.786622	5.40E-1	Positiv
	4.3	784	20	e
MAP3K7	AC01083	0.711956	1.73E-8	Positiv
	4.3	689	8	e
BCL2L11	AC01083	0.451263	1.08E-2	Positiv
	4.3	683	9	e
TSC1	AC01083	0.420116	1.44E-2	Positiv
	4.3	928	5	e
CYLD	AC01083	0.660358	4.73E-7	Positiv
	4.3	69	2	e
IPMK	AC01083	0.639669	2.42E-6	Positiv
	4.3	861	6	e
KLF9	AC01083	0.438042	6.86E-2	Positiv
	4.3	226	8	e
BRAF	AC01083	0.816922	1.12E-1	Positiv
	4.3	033	36	e
SIRT1	AC01083	0.438846	5.35E-2	Positiv
	4.3	881	8	e
CFLAR	AC01083	0.681442	2.34E-7	Positiv
	4.3	528	8	e

MAPK8	AL35507	0.642414	4.49E-6	Positiv
	5.2	498	7	e
ATRX	AL35507	0.715708	7.97E-9	Positiv
	5.2	124	0	e
OTULIN	AL35507	0.783091	3.16E-1	Positiv
	5.2	082	18	e
MAP3K7	AL35507	0.663875	4.56E-7	Positiv
	5.2	928	3	e
BCL2L11	AL35507	0.487864	4.02E-3	Positiv
	5.2	262	5	e
CYLD	AL35507	0.667952	2.91E-7	Positiv
	5.2	549	4	e
IPMK	AL35507	0.609736	8.11E-5	Positiv
	5.2	483	9	e
KLF9	AL35507	0.427834	1.50E-2	Positiv
	5.2	196	6	e
BRAF	AL35507	0.775951	9.38E-1	Positiv
	5.2	204	15	e
CFLAR	AL35507	0.678920	1.42E-7	Positiv
	5.2	196	7	e
MAPK8	AC01076	0.424432	4.10E-2	Positiv
	1.1	863	6	e
ATRX	AC01076	0.415142	6.02E-2	Positiv
	1.1	836	5	e
OTULIN	AC01076	0.542234	1.68E-4	Positiv
	1.1	467	4	e
MAP3K7	AC01076	0.406698	6.44E-2	Positiv
	1.1	24	4	e
TSC1	AC01076	0.495993	2.03E-3	Positiv
	1.1	101	6	e
BRAF	AC01076	0.546034	3.20E-4	Positiv

	1.1	933	5	e
CFLAR	AC01076	0.501823	2.27E-3	Positiv
	1.1	794	7	e
CFLAR	LINC012	0.409935	2.62E-2	Positiv
	32	643	4	e
MAPK8	HIF1A-	0.445735	6.25E-2	Positiv
	AS2	8	9	e
ATRX	HIF1A-	0.422937	6.35E-2	Positiv
	AS2	652	6	e
OTULIN	HIF1A-	0.632386	1.96E-6	Positiv
	AS2	302	4	e
MAP3K7	HIF1A-	0.491746	9.75E-3	Positiv
	AS2	663	6	e
CYLD	HIF1A-	0.512859	3.18E-3	Positiv
	AS2	635	9	e
IPMK	HIF1A-	0.405149	9.88E-2	Positiv
	AS2	399	4	e
KLF9	HIF1A-	0.405278	9.53E-2	Positiv
	AS2	507	4	e
BRAF	HIF1A-	0.525423	2.04E-4	Positiv
	AS2	162	1	e
CFLAR	HIF1A-	0.505473	5.62E-3	Positiv
	AS2	076	8	e
TSC1	AC09211	0.528891	4.86E-4	Positiv
	9.2	556	2	e
MAPK8	FTX	0.617056	1.39E-6	Positiv
		55	0	e
ATRX	FTX	0.845387	1.88E-1	Positiv
		653	55	e
OTULIN	FTX	0.724811	3.67E-9	Positiv
		327	3	e

MAP3K7	FTX	0.602367	4.37E-5	Positiv
		294	7	e
CYLD	FTX	0.631632	3.06E-6	Positiv
		596	4	e
IPMK	FTX	0.600402	1.24E-5	Positiv
		836	6	e
BRAF	FTX	0.795084	2.29E-1	Positiv
		211	24	e
CFLAR	FTX	0.616647	1.75E-6	Positiv
		181	0	e
MAPK8	AL04953 9.1	0.624897	1.59E-6	Positiv
		599	2	e
ATRX	AL04953 9.1	0.764521	1.87E-1	Positiv
		601	09	e
OTULIN	AL04953 9.1	0.787718	1.51E-1	Positiv
		438	20	e
MAP3K7	AL04953 9.1	0.631367	3.58E-6	Positiv
		549	4	e
BCL2L11	AL04953 9.1	0.454590	3.67E-3	Positiv
		413	0	e
CYLD	AL04953 9.1	0.653158	5.16E-7	Positiv
		993	0	e
IPMK	AL04953 9.1	0.599328	2.19E-5	Positiv
		866	6	e
BRAF	AL04953 9.1	0.830583	3.00E-1	Positiv
		566	45	e
CFLAR	AL04953 9.1	0.649214	6.39E-6	Positiv
		927	9	e
MAPK8	AC00703 8.2	0.619310	3.90E-6	Positiv
		028	1	e
ATRX	AC00703	0.720138	1.97E-9	Positiv

	8.2	369	1	e
OTULIN	AC00703	0.718021	1.16E-9	Positiv
	8.2	428	0	e
MAP3K7	AC00703	0.694466	1.59E-8	Positiv
	8.2	548	2	e
CYLD	AC00703	0.592363	8.30E-5	Positiv
	8.2	977	5	e
IPMK	AC00703	0.637261	1.05E-6	Positiv
	8.2	685	5	e
BRAF	AC00703	0.744620	6.54E-1	Positiv
	8.2	057	01	e
SIRT1	AC00703	0.414408	7.42E-2	Positiv
	8.2	429	5	e
CFLAR	AC00703	0.646299	4.01E-6	Positiv
	8.2	832	8	e
OTULIN	ZDHHC	0.466434	7.27E-3	Positiv
	20-IT1	007	2	e
MAPK8	AL03171	0.484633	1.29E-3	Positiv
	6.1	206	4	e
ATRX	AL03171	0.644223	1.46E-6	Positiv
	6.1	233	7	e
OTULIN	AL03171	0.529178	4.31E-4	Positiv
	6.1	452	2	e
MAP3K7	AL03171	0.424721	3.76E-2	Positiv
	6.1	8	6	e
CYLD	AL03171	0.461160	4.25E-3	Positiv
	6.1	165	1	e
FADD	AL03171	-0.40308	1.74E-2	Negati
	6.1	2169	3	ve
IPMK	AL03171	0.462358	2.85E-3	Positiv
	6.1	448	1	e

BRAF	AL03171	0.647071	2.47E-6	Positiv
	6.1	526	8	e
CFLAR	AL03171	0.543496	9.71E-4	Positiv
	6.1	549	5	e
MAPK8	AL08031	0.651520	1.48E-6	Positiv
	7.2	003	9	e
ATRX	AL08031	0.733821	1.34E-9	Positiv
	7.2	528	6	e
OTULIN	AL08031	0.828243	9.97E-1	Positiv
	7.2	599	44	e
MAP3K7	AL08031	0.712700	9.45E-8	Positiv
	7.2	059	9	e
BCL2L11	AL08031	0.433888	2.44E-2	Positiv
	7.2	312	7	e
CYLD	AL08031	0.666740	6.62E-7	Positiv
	7.2	194	4	e
IPMK	AL08031	0.617236	1.26E-6	Positiv
	7.2	454	0	e
KLF9	AL08031	0.434269	2.17E-2	Positiv
	7.2	661	7	e
BRAF	AL08031	0.807675	2.85E-1	Positiv
	7.2	034	31	e
CFLAR	AL08031	0.683857	4.10E-7	Positiv
	7.2	553	9	e
MAP3K7	AL13908	0.455256	2.96E-3	Positiv
	9.1	264	0	e
MAPK8	AC08727	0.509994	9.77E-3	Positiv
	7.2	861	9	e
ATRX	AC08727	0.568697	1.01E-4	Positiv
	7.2	824	9	e
OTULIN	AC08727	0.628853	1.58E-6	Positiv

	7.2	82	3	e
MAP3K7	AC08727	0.493774	4.62E-3	Positiv
	7.2	491	6	e
BCL2L11	AC08727	0.410709	2.11E-2	Positiv
	7.2	248	4	e
TSC1	AC08727	0.469938	2.21E-3	Positiv
	7.2	382	2	e
CYLD	AC08727	0.513539	2.43E-3	Positiv
	7.2	523	9	e
IPMK	AC08727	0.468284	3.88E-3	Positiv
	7.2	612	2	e
BRAF	AC08727	0.660813	3.50E-7	Positiv
	7.2	763	2	e
CFLAR	AC08727	0.583691	6.78E-5	Positiv
	7.2	999	3	e
SPATA2	AL13352	0.551496	2.83E-4	Positiv
	0.1	952	6	e
MAPK8	THUMP	0.473814	5.83E-3	Positiv
	D3-AS1	369	3	e
ATRX	THUMP	0.561079	3.60E-4	Positiv
	D3-AS1	805	8	e
OTULIN	THUMP	0.579515	5.39E-5	Positiv
	D3-AS1	744	2	e
MAP3K7	THUMP	0.599959	1.57E-5	Positiv
	D3-AS1	549	6	e
ITPK1	THUMP	-0.47258	8.90E-3	Negati
	D3-AS1	9641	3	ve
TSC1	THUMP	0.557033	2.31E-4	Positiv
	D3-AS1	806	7	e
CYLD	THUMP	0.406727	6.39E-2	Positiv
	D3-AS1	044	4	e

IPMK	THUMP	0.450012	1.61E-2	Positiv
	D3-AS1	539	9	e
BRAF	THUMP	0.628984	1.46E-6	Positiv
	D3-AS1	151	3	e
CFLAR	THUMP	0.588293	6.67E-5	Positiv
	D3-AS1	35	4	e
AXL	LINC017	0.581987	1.59E-5	Positiv
	05	162	2	e
MAPK8	AL02232	0.479454	8.13E-3	Positiv
	2.1	759	4	e
ATRX	AL02232	0.506230	4.20E-3	Positiv
	2.1	289	8	e
OTULIN	AL02232	0.544461	6.37E-4	Positiv
	2.1	721	5	e
BCL2L11	AL02232	0.427820	1.51E-2	Positiv
	2.1	075	6	e
TSC1	AL02232	0.534097	5.49E-4	Positiv
	2.1	621	3	e
CYLD	AL02232	0.449571	1.85E-2	Positiv
	2.1	222	9	e
BRAF	AL02232	0.646643	3.23E-6	Positiv
	2.1	273	8	e
CFLAR	AL02232	0.650866	2.24E-6	Positiv
	2.1	748	9	e
ATRX	AC07395	0.454034	4.40E-3	Positiv
	7.3	087	0	e
MAP3K7	AC07395	0.401928	2.39E-2	Positiv
	7.3	317	3	e
EGFR	AC07395	0.425845	2.70E-2	Positiv
	7.3	525	6	e
TSC1	AC07395	0.556024	3.66E-4	Positiv

	7.3	326	7	e
BRAF	AC07395	0.485476	9.52E-3	Positiv
	7.3	903	5	e
CFLAR	AC07395	0.507784	2.31E-3	Positiv
	7.3	87	8	e
SPATA2	AL12183	0.432320	3.92E-2	Positiv
	2.3	781	7	e
MAPK8	AL07858	0.438478	6.00E-2	Positiv
	7.1	384	8	e
ATRX	AL07858	0.690586	2.92E-8	Positiv
	7.1	571	1	e
OTULIN	AL07858	0.577708	1.31E-5	Positiv
	7.1	451	1	e
MAP3K7	AL07858	0.503714	1.10E-3	Positiv
	7.1	049	7	e
TSC1	AL07858	0.407517	5.13E-2	Positiv
	7.1	075	4	e
CYLD	AL07858	0.477393	1.68E-3	Positiv
	7.1	943	3	e
BRAF	AL07858	0.646473	3.60E-6	Positiv
	7.1	717	8	e
CFLAR	AL07858	0.604995	1.07E-5	Positiv
	7.1	694	7	e
STUB1	AP00145	0.411525	1.68E-2	Positiv
	3.2	196	4	e
MPG	AP00145	0.465490	9.99E-3	Positiv
	3.2	708	2	e
MAPK8	GK-AS1	0.530150	2.88E-4	Positiv
		459	2	e
ATRX	GK-AS1	0.518424	3.48E-4	Positiv
		639	0	e

OTULIN	GK-AS1	0.668184	2.48E-7	Positiv
		163	4	e
MAP3K7	GK-AS1	0.530930	2.08E-4	Positiv
		069	2	e
BCL2L11	GK-AS1	0.424746	3.74E-2	Positiv
		562	6	e
CYLD	GK-AS1	0.622857	5.14E-6	Positiv
		709	2	e
IPMK	GK-AS1	0.481807	3.53E-3	Positiv
		857	4	e
KLF9	GK-AS1	0.473583	6.31E-3	Positiv
		108	3	e
BRAF	GK-AS1	0.633441	1.04E-6	Positiv
		549	4	e
CFLAR	GK-AS1	0.586329	1.80E-5	Positiv
		308	3	e
MAPK8	LINC005	0.513908	2.10E-3	Positiv
	78	844	9	e
PANX1	LINC005	0.444904	8.12E-2	Positiv
	78	657	9	e
ATRX	LINC005	0.636989	1.24E-6	Positiv
	78	624	5	e
OTULIN	LINC005	0.603043	3.04E-5	Positiv
	78	068	7	e
MAP3K7	LINC005	0.544831	5.42E-4	Positiv
	78	468	5	e
AXL	LINC005	0.483825	1.72E-3	Positiv
	78	141	4	e
BCL2L11	LINC005	0.447718	3.34E-2	Positiv
	78	993	9	e
CYLD	LINC005	0.698818	5.72E-8	Positiv

	78	849	4	e
IPMK	LINC005	0.419562	1.69E-2	Positiv
	78	796	5	e
KLF9	LINC005	0.631904	2.61E-6	Positiv
	78	79	4	e
BRAF	LINC005	0.613670	9.24E-6	Positiv
	78	93	0	e
CFLAR	LINC005	0.643630	2.12E-6	Positiv
	78	314	7	e
MAPK8	ACBD3-	0.654313	2.45E-7	Positiv
	AS1	813	0	e
ATRX	ACBD3-	0.629415	1.14E-6	Positiv
	AS1	444	3	e
OTULIN	ACBD3-	0.684575	2.43E-7	Positiv
	AS1	435	9	e
MAP3K7	ACBD3-	0.594241	3.14E-5	Positiv
	AS1	552	5	e
BCL2L11	ACBD3-	0.432966	3.22E-2	Positiv
	AS1	153	7	e
CYLD	ACBD3-	0.624907	1.58E-6	Positiv
	AS1	449	2	e
IPMK	ACBD3-	0.580581	3.19E-5	Positiv
	AS1	596	2	e
KLF9	ACBD3-	0.441025	2.73E-2	Positiv
	AS1	892	8	e
BRAF	ACBD3-	0.715379	1.05E-8	Positiv
	AS1	24	9	e
CFLAR	ACBD3-	0.667414	4.19E-7	Positiv
	AS1	725	4	e
MAPK8	RUSC1-	0.441262	2.53E-2	Positiv
	AS1	209	8	e

ATRX	RUSC1-	0.515027	1.35E-3	Positiv
	AS1	556	9	e
OTULIN	RUSC1-	0.619755	3.03E-6	Positiv
	AS1	201	1	e
MAP3K7	RUSC1-	0.461158	4.25E-3	Positiv
	AS1	14	1	e
TSC1	RUSC1-	0.477084	1.87E-3	Positiv
	AS1	561	3	e
CYLD	RUSC1-	0.436299	1.17E-2	Positiv
	AS1	177	7	e
IPMK	RUSC1-	0.448026	3.02E-2	Positiv
	AS1	691	9	e
BRAF	RUSC1-	0.602430	4.22E-5	Positiv
	AS1	782	7	e
CFLAR	RUSC1-	0.595379	1.74E-5	Positiv
	AS1	487	5	e
MAPK8	AL10961	0.630897	4.74E-6	Positiv
	4.1	266	4	e
ATRX	AL10961	0.724066	6.96E-9	Positiv
	4.1	468	3	e
OTULIN	AL10961	0.796008	7.39E-1	Positiv
	4.1	451	25	e
MAP3K7	AL10961	0.698050	1.03E-8	Positiv
	4.1	327	3	e
BCL2L11	AL10961	0.453442	5.33E-3	Positiv
	4.1	202	0	e
TSC1	AL10961	0.455971	2.34E-3	Positiv
	4.1	5	0	e
CYLD	AL10961	0.665313	1.73E-7	Positiv
	4.1	611	3	e
IPMK	AL10961	0.594448	2.82E-5	Positiv

	4.1	256	5	e
BRAF	AL10961	0.836507	3.29E-1	Positiv
	4.1	531	49	e
CFLAR	AL10961	0.705081	4.31E-8	Positiv
	4.1	463	6	e
MAPK8	AC07348	0.606118	5.81E-5	Positiv
	7.1	138	8	e
ATRX	AC07348	0.639479	2.72E-6	Positiv
	7.1	648	6	e
OTULIN	AC07348	0.731242	1.33E-9	Positiv
	7.1	666	5	e
MAP3K7	AC07348	0.525979	1.62E-4	Positiv
	7.1	513	1	e
BCL2L11	AC07348	0.512373	3.85E-3	Positiv
	7.1	194	9	e
CYLD	AC07348	0.637767	7.72E-6	Positiv
	7.1	548	6	e
IPMK	AC07348	0.528650	5.37E-4	Positiv
	7.1	037	2	e
KLF9	AC07348	0.420731	1.21E-2	Positiv
	7.1	704	5	e
BRAF	AC07348	0.764167	2.70E-1	Positiv
	7.1	359	09	e
CFLAR	AC07348	0.702200	4.15E-8	Positiv
	7.1	543	5	e
MAPK8	LINC-PI	0.671837	2.02E-7	Positiv
	NT	734	5	e
ATRX	LINC-PI	0.710264	6.84E-8	Positiv
	NT	498	8	e
OTULIN	LINC-PI	0.798196	4.99E-1	Positiv
	NT	455	26	e

MAP3K7	LINC-PI	0.644906	9.58E-6	Positiv
	NT	33	8	e
BCL2L11	LINC-PI	0.481433	4.04E-3	Positiv
	NT	592	4	e
CYLD	LINC-PI	0.701909	5.21E-8	Positiv
	NT	856	5	e
IPMK	LINC-PI	0.615290	3.75E-6	Positiv
	NT	091	0	e
KLF9	LINC-PI	0.408657	3.74E-2	Positiv
	NT	104	4	e
BRAF	LINC-PI	0.872796	1.61E-1	Positiv
	NT	523	77	e
CFLAR	LINC-PI	0.712842	8.42E-8	Positiv
	NT	13	9	e
MAP3K7	AC00633	0.477838	1.43E-3	Positiv
	3.2	5	3	e
IPMK	AC00633	0.406821	6.23E-2	Positiv
	3.2	65	4	e
BRAF	AC00633	0.457763	1.30E-3	Positiv
	3.2	472	0	e
MAPK8	MIR17H	0.600643	1.09E-5	Positiv
	G	794	6	e
ATRX	MIR17H	0.694203	1.94E-8	Positiv
	G	693	2	e
OTULIN	MIR17H	0.772744	3.10E-1	Positiv
	G	298	13	e
MAP3K7	MIR17H	0.704846	5.20E-8	Positiv
	G	102	6	e
CYLD	MIR17H	0.603725	2.11E-5	Positiv
	G	593	7	e
IPMK	MIR17H	0.598109	4.17E-5	Positiv

	G	508	6	e
BRAF	MIR17H	0.761141	6.05E-1	Positiv
	G	902	08	e
CFLAR	MIR17H	0.627386	3.73E-6	Positiv
	G	843	3	e
TSC1	AL92865	0.569740	6.16E-5	Positiv
	4.2	743	0	e
BRAF	AL92865	0.409534	2.93E-2	Positiv
	4.2	554	4	e
CFLAR	AL92865	0.491038	1.26E-3	Positiv
	4.2	977	5	e
MAPK8	LMO7-A	0.488382	3.33E-3	Positiv
	S1	982	5	e
ATRX	LMO7-A	0.597091	7.11E-5	Positiv
	S1	824	6	e
OTULIN	LMO7-A	0.596883	7.93E-5	Positiv
	S1	014	6	e
MAP3K7	LMO7-A	0.594252	3.13E-5	Positiv
	S1	578	5	e
CYLD	LMO7-A	0.514034	2.00E-3	Positiv
	S1	42	9	e
IPMK	LMO7-A	0.475293	3.49E-3	Positiv
	S1	574	3	e
BRAF	LMO7-A	0.590598	2.06E-5	Positiv
	S1	383	4	e
CFLAR	LMO7-A	0.545072	4.88E-4	Positiv
	S1	048	5	e
ATRX	AL11737	0.536544	1.94E-4	Positiv
	9.1	242	3	e
OTULIN	AL11737	0.608727	1.41E-5	Positiv
	9.1	113	8	e

MAP3K7	AL11737	0.559624	7.05E-4	Positiv
	9.1	675	8	e
TSC1	AL11737	0.460065	6.10E-3	Positiv
	9.1	932	1	e
CYLD	AL11737	0.429410	9.38E-2	Positiv
	9.1	508	7	e
BRAF	AL11737	0.634199	6.63E-6	Positiv
	9.1	419	5	e
CFLAR	AL11737	0.549259	7.68E-4	Positiv
	9.1	415	6	e
MAPK8	AC01908	0.640128	1.83E-6	Positiv
	0.5	097	6	e
ATRX	AC01908	0.742000	7.61E-1	Positiv
	0.5	719	00	e
OTULIN	AC01908	0.720048	2.12E-9	Positiv
	0.5	424	1	e
MAP3K7	AC01908	0.696126	4.50E-8	Positiv
	0.5	852	3	e
CYLD	AC01908	0.593359	4.96E-5	Positiv
	0.5	59	5	e
IPMK	AC01908	0.650905	2.18E-6	Positiv
	0.5	257	9	e
BRAF	AC01908	0.759947	2.04E-1	Positiv
	0.5	189	07	e
SIRT1	AC01908	0.432106	4.18E-2	Positiv
	0.5	217	7	e
CFLAR	AC01908	0.608143	1.94E-5	Positiv
	0.5	401	8	e
BRAF	AC12176	0.403965	1.37E-2	Positiv
	1.1	841	3	e
OTULIN	HM13-IT	0.440534	3.18E-2	Positiv

	1	115	8	e
TSC1	HM13-IT	0.483912	1.67E-3	Positiv
	1	036	4	e
BRAF	HM13-IT	0.462985	2.31E-3	Positiv
	1	202	1	e
CFLAR	HM13-IT	0.529027	4.60E-4	Positiv
	1	076	2	e
TRAF2	AC01677	0.429262	9.80E-2	Positiv
	3.1	453	7	e
ATRX	AC23227	0.495554	2.39E-3	Positiv
	1.1	045	6	e
OTULIN	AC23227	0.418096	2.58E-2	Positiv
	1.1	511	5	e
MAP3K7	AC23227	0.405504	8.96E-2	Positiv
	1.1	691	4	e
TSC1	AC23227	0.533108	8.33E-4	Positiv
	1.1	193	3	e
BRAF	AC23227	0.490652	1.46E-3	Positiv
	1.1	073	5	e
CFLAR	AC23227	0.486554	6.46E-3	Positiv
	1.1	217	5	e
MAPK8	AC10469	0.459977	6.28E-3	Positiv
	5.3	814	1	e
ATRX	AC10469	0.459948	6.35E-3	Positiv
	5.3	256	1	e
OTULIN	AC10469	0.585100	3.35E-5	Positiv
	5.3	322	3	e
MAP3K7	AC10469	0.407599	5.02E-2	Positiv
	5.3	978	4	e
CYLD	AC10469	0.509933	1.00E-3	Positiv
	5.3	912	8	e

IPMK	AC10469	0.406007	7.80E-2	Positiv
	5.3	144	4	e
BRAF	AC10469	0.616232	2.21E-6	Positiv
	5.3	475	0	e
CFLAR	AC10469	0.545944	3.33E-4	Positiv
	5.3	286	5	e
ATRX	AC00604	0.449097	2.15E-2	Positiv
	2.1	361	9	e
MAP3K7	AC00604	0.438650	5.69E-2	Positiv
	2.1	814	8	e
TSC1	AC00604	0.578540	8.72E-5	Positiv
	2.1	019	2	e
BRAF	AC00604	0.477607	1.56E-3	Positiv
	2.1	932	3	e
CFLAR	AC00604	0.535617	2.88E-4	Positiv
	2.1	733	3	e
MAPK8	MBNL1-	0.402087	2.29E-2	Positiv
	AS1	06	3	e
ATRX	MBNL1-	0.536579	1.92E-4	Positiv
	AS1	72	3	e
OTULIN	MBNL1-	0.422944	6.34E-2	Positiv
	AS1	421	6	e
CYLD	MBNL1-	0.521767	9.04E-4	Positiv
	AS1	896	1	e
KLF9	MBNL1-	0.600619	1.11E-5	Positiv
	AS1	727	6	e
BRAF	MBNL1-	0.521143	1.16E-4	Positiv
	AS1	858	0	e
CFLAR	MBNL1-	0.462052	3.16E-3	Positiv
	AS1	575	1	e
MAPK8	AC00763	0.424064	4.57E-2	Positiv

	7.1	618	6	e
ATRX	AC00763	0.496107	1.94E-3	Positiv
	7.1	968	6	e
OTULIN	AC00763	0.529837	3.28E-4	Positiv
	7.1	331	2	e
MAP3K7	AC00763	0.498955	6.70E-3	Positiv
	7.1	817	7	e
TSC1	AC00763	0.479530	7.91E-3	Positiv
	7.1	02	4	e
CYLD	AC00763	0.481207	4.37E-3	Positiv
	7.1	38	4	e
BRAF	AC00763	0.616225	2.22E-6	Positiv
	7.1	5	0	e
CFLAR	AC00763	0.589762	3.15E-5	Positiv
	7.1	041	4	e
MAPK8	AL35548	0.630596	5.66E-6	Positiv
	8.1	973	4	e
ATRX	AL35548	0.692586	6.55E-8	Positiv
	8.1	912	2	e
OTULIN	AL35548	0.769634	8.70E-1	Positiv
	8.1	104	12	e
MAP3K7	AL35548	0.629615	1.01E-6	Positiv
	8.1	758	3	e
BCL2L11	AL35548	0.444078	1.05E-2	Positiv
	8.1	729	8	e
TSC1	AL35548	0.472229	1.01E-3	Positiv
	8.1	617	2	e
CYLD	AL35548	0.601883	5.65E-5	Positiv
	8.1	549	7	e
FADD	AL35548	-0.42973	8.52E-2	Negati
	8.1	1662	7	ve

IPMK	AL35548	0.586542	1.62E-5	Positiv
	8.1	425	3	e
BRAF	AL35548	0.784322	7.72E-1	Positiv
	8.1	477	19	e
CFLAR	AL35548	0.639126	3.38E-6	Positiv
	8.1	549	6	e
ATRX	PLAC4	0.427539	1.64E-2	Positiv
		093	6	e
OTULIN	PLAC4	0.487607	4.41E-3	Positiv
		952	5	e
BCL2L11	PLAC4	0.448003	3.05E-2	Positiv
		913	9	e
TSC1	PLAC4	0.429572	8.94E-2	Positiv
		349	7	e
CYLD	PLAC4	0.440979	2.77E-2	Positiv
		958	8	e
BRAF	PLAC4	0.540301	3.88E-4	Positiv
		916	4	e
CFLAR	PLAC4	0.624099	2.51E-6	Positiv
		691	2	e
ATRX	AC12302	0.470743	1.68E-3	Positiv
	3.1	634	2	e
MAP3K7	AC12302	0.427659	1.58E-2	Positiv
	3.1	387	6	e
BRAF	AC12302	0.457203	1.57E-3	Positiv
	3.1	784	0	e
MAPK8	AP00078	0.615184	3.98E-6	Positiv
	6.1	212	0	e
ATRX	AP00078	0.657245	3.65E-7	Positiv
	6.1	843	1	e
OTULIN	AP00078	0.719434	3.56E-9	Positiv

	6.1	593	1	e
MAP3K7	AP00078	0.512087	4.31E-3	Positiv
	6.1	552	9	e
BCL2L11	AP00078	0.454337	3.99E-3	Positiv
	6.1	474	0	e
CYLD	AP00078	0.652480	7.98E-7	Positiv
	6.1	835	0	e
IPMK	AP00078	0.588003	7.73E-5	Positiv
	6.1	143	4	e
BRAF	AP00078	0.742387	5.31E-1	Positiv
	6.1	433	00	e
CFLAR	AP00078	0.628500	1.94E-6	Positiv
	6.1	488	3	e
TSC1	LINC001	0.437686	7.65E-2	Positiv
	06	487	8	e
ID1	GATA2-	0.413579	9.38E-2	Positiv
	AS1	789	5	e
MAPK8	AL15883	0.427709	1.56E-2	Positiv
	7.1	994	6	e
ATRX	AL15883	0.413923	8.51E-2	Positiv
	7.1	488	5	e
OTULIN	AL15883	0.483316	2.06E-3	Positiv
	7.1	646	4	e
TSC1	AL15883	0.456302	2.10E-3	Positiv
	7.1	68	0	e
CYLD	AL15883	0.435206	1.63E-2	Positiv
	7.1	293	7	e
BRAF	AL15883	0.565132	5.45E-4	Positiv
	7.1	871	9	e
CFLAR	AL15883	0.592114	9.44E-5	Positiv
	7.1	655	5	e

MAPK8	AL60683	0.449659	1.80E-2	Positiv
	4.1	889	9	e
OTULIN	AL60683	0.424841	3.63E-2	Positiv
	4.1	545	6	e
BCL2L11	AL60683	0.414024	8.27E-2	Positiv
	4.1	594	5	e
CYLD	AL60683	0.451654	9.49E-3	Positiv
	4.1	093	0	e
BRAF	AL60683	0.524472	3.00E-4	Positiv
	4.1	945	1	e
CFLAR	AL60683	0.524012	3.63E-4	Positiv
	4.1	848	1	e
MAPK8	AC01167	0.454791	3.44E-3	Positiv
	6.1	688	0	e
ATRX	AC01167	0.493886	4.43E-3	Positiv
	6.1	191	6	e
OTULIN	AC01167	0.565750	4.08E-4	Positiv
	6.1	399	9	e
MAP3K7	AC01167	0.406336	7.12E-2	Positiv
	6.1	55	4	e
BCL2L11	AC01167	0.466189	7.89E-3	Positiv
	6.1	971	2	e
CYLD	AC01167	0.505199	6.25E-3	Positiv
	6.1	526	8	e
BRAF	AC01167	0.602078	5.09E-5	Positiv
	6.1	479	7	e
CFLAR	AC01167	0.584940	3.63E-5	Positiv
	6.1	393	3	e
MAPK8	AL13324	0.676238	9.43E-7	Positiv
	3.2	342	7	e
ATRX	AL13324	0.810511	6.73E-1	Positiv

	3.2	353	33	e
OTULIN	AL13324	0.830329	4.40E-1	Positiv
	3.2	253	45	e
MAP3K7	AL13324	0.701432	7.56E-8	Positiv
	3.2	34	5	e
BCL2L11	AL13324	0.467379	5.28E-3	Positiv
	3.2	863	2	e
CYLD	AL13324	0.724005	7.33E-9	Positiv
	3.2	061	3	e
FADD	AL13324	-0.40454	1.17E-2	Negati
	3.2	9172	3	ve
IPMK	AL13324	0.675961	1.15E-7	Positiv
	3.2	184	6	e
KLF9	AL13324	0.467039	5.92E-3	Positiv
	3.2	817	2	e
BRAF	AL13324	0.859215	5.33E-1	Positiv
	3.2	754	66	e
SIRT1	AL13324	0.414668	6.89E-2	Positiv
	3.2	058	5	e
CFLAR	AL13324	0.710025	8.30E-8	Positiv
	3.2	155	8	e
MAPK8	AC13893	0.594527	2.71E-5	Positiv
	2.5	815	5	e
ATRX	AC13893	0.652724	6.82E-7	Positiv
	2.5	605	0	e
OTULIN	AC13893	0.750649	2.06E-1	Positiv
	2.5	736	03	e
MAP3K7	AC13893	0.608973	1.23E-5	Positiv
	2.5	149	8	e
BCL2L11	AC13893	0.494717	3.26E-3	Positiv
	2.5	385	6	e

TSC1	AC13893	0.465749	9.15E-3	Positiv
	2.5	619	2	e
CYLD	AC13893	0.636565	1.60E-6	Positiv
	2.5	536	5	e
IPMK	AC13893	0.494447	3.60E-3	Positiv
	2.5	494	6	e
KLF9	AC13893	0.417792	2.82E-2	Positiv
	2.5	688	5	e
BRAF	AC13893	0.755944	1.14E-1	Positiv
	2.5	752	05	e
CFLAR	AC13893	0.773898	8.86E-1	Positiv
	2.5	065	14	e
MAPK8	AC00459	0.448568	2.55E-2	Positiv
	3.1	687	9	e
ATRX	AC00459	0.661927	1.67E-7	Positiv
	3.1	752	2	e
OTULIN	AC00459	0.579933	4.39E-5	Positiv
	3.1	153	2	e
MAP3K7	AC00459	0.580171	3.90E-5	Positiv
	3.1	094	2	e
CYLD	AC00459	0.460552	5.20E-3	Positiv
	3.1	671	1	e
IPMK	AC00459	0.457863	1.26E-3	Positiv
	3.1	565	0	e
BRAF	AC00459	0.582137	1.47E-5	Positiv
	3.1	022	2	e
CFLAR	AC00459	0.549474	6.98E-4	Positiv
	3.1	78	6	e
MAPK8	AL13868	0.489723	2.05E-3	Positiv
	9.1	214	5	e
ATRX	AL13868	0.516846	6.55E-4	Positiv

	9.1	187	0	e
OTULIN	AL13868	0.702862	2.47E-8	Positiv
	9.1	215	5	e
MAP3K7	AL13868	0.591599	1.23E-5	Positiv
	9.1	838	4	e
CYLD	AL13868	0.521127	1.17E-4	Positiv
	9.1	689	0	e
IPMK	AL13868	0.441653	2.24E-2	Positiv
	9.1	209	8	e
BRAF	AL13868	0.592752	6.79E-5	Positiv
	9.1	556	5	e
CFLAR	AL13868	0.588408	6.29E-5	Positiv
	9.1	483	4	e
ATRX	AC09105	0.433596	2.66E-2	Positiv
	7.1	241	7	e
OTULIN	AC09105	0.492783	6.66E-3	Positiv
	7.1	114	6	e
MAP3K7	AC09105	0.406807	6.25E-2	Positiv
	7.1	823	4	e
MPG	AC09105	-0.43295	3.23E-2	Negati
	7.1	7794	7	ve
TSC1	AC09105	0.525355	2.09E-4	Positiv
	7.1	949	1	e
BRAF	AC09105	0.501740	2.34E-3	Positiv
	7.1	574	7	e
CFLAR	AC09105	0.550981	3.56E-4	Positiv
	7.1	919	6	e
MAPK8	LINC013	0.649515	5.28E-6	Positiv
	55	524	9	e
ATRX	LINC013	0.766290	2.96E-1	Positiv
	55	538	10	e

OTULIN	LINC013	0.762673	1.26E-1	Positiv
	55	054	08	e
MAP3K7	LINC013	0.676097	1.04E-7	Positiv
	55	832	6	e
BCL2L11	LINC013	0.435319	1.58E-2	Positiv
	55	9	7	e
TSC1	LINC013	0.473167	7.29E-3	Positiv
	55	681	3	e
CYLD	LINC013	0.621893	8.94E-6	Positiv
	55	636	2	e
IPMK	LINC013	0.599591	1.91E-5	Positiv
	55	415	6	e
BRAF	LINC013	0.782353	7.32E-1	Positiv
	55	675	18	e
SIRT1	LINC013	0.407174	5.65E-2	Positiv
	55	35	4	e
CFLAR	LINC013	0.702763	2.67E-8	Positiv
	55	414	5	e
TRIM11	PTOV1-	0.404932	1.05E-2	Positiv
	AS2	608	3	e
MAPK8	Z82243.1	0.536564	1.93E-4	Positiv
		807	3	e
ATRX	Z82243.1	0.602386	4.32E-5	Positiv
		233	7	e
OTULIN	Z82243.1	0.690471	3.18E-8	Positiv
		229	1	e
MAP3K7	Z82243.1	0.529722	3.44E-4	Positiv
		379	2	e
BCL2L11	Z82243.1	0.499059	6.44E-3	Positiv
		442	7	e
TSC1	Z82243.1	0.530310	2.69E-4	Positiv

		503	2	e	
CYLD	Z82243.1	0.554498	7.32E-4	Positiv	
		043	7	e	
IPMK	Z82243.1	0.446993	4.20E-2	Positiv	
		131	9	e	
BRAF	Z82243.1	0.718853	5.80E-9	Positiv	
		602	1	e	
CFLAR	Z82243.1	0.723741	9.19E-9	Positiv	
		774	3	e	
CFLAR	MIRLET	0.455179	3.03E-3	Positiv	
	7BHG	113	0	e	
TSC1	AP00146	0.403063	1.75E-2	Positiv	
	9.3	439	3	e	
MAPK8	AC00734	0.426605	2.16E-2	Positiv	
	2.5	943	6	e	
OTULIN	AC00734	0.436631	1.06E-2	Positiv	
	2.5	285	7	e	
IPMK	AC00734	0.510068	9.49E-3	Positiv	
	2.5	464	9	e	
BRAF	AC00734	0.454086	4.32E-3	Positiv	
	2.5	38	0	e	
MAPK8	AP00589	0.528822	5.00E-4	Positiv	
	9.1	478	2	e	
ATRX	AP00589	0.473590	6.30E-3	Positiv	
	9.1	001	3	e	
OTULIN	AP00589	0.564687	6.71E-4	Positiv	
	9.1	786	9	e	
MAP3K7	AP00589	0.400280	3.73E-2	Positiv	
	9.1	274	3	e	
BCL2L11	AP00589	0.527903	7.32E-4	Positiv	
	9.1	006	2	e	

TSC1	AP00589	0.441890	2.08E-2	Positiv
	9.1	18	8	e
CYLD	AP00589	0.553668	1.07E-4	Positiv
	9.1	058	6	e
BRAF	AP00589	0.640755	1.25E-6	Positiv
	9.1	23	6	e
CFLAR	AP00589	0.656278	6.86E-7	Positiv
	9.1	859	1	e
OTULIN	AP00335	0.450103	1.56E-2	Positiv
	2.1	085	9	e
MAP3K7	AP00335	0.429049	1.04E-2	Positiv
	2.1	451	6	e
KIAA1429	AP00335	0.421862	8.69E-2	Positiv
	2.1	491	6	e
BRAF	AP00335	0.406783	6.29E-2	Positiv
	2.1	962	4	e
RIPK1	LINC013	-0.42894	1.08E-2	Negati
	15	1319	6	ve
MAPK8	PSPC1-A	0.543905	8.12E-4	Positiv
	S2	63	5	e
ATRX	PSPC1-A	0.624120	2.48E-6	Positiv
	S2	98	2	e
OTULIN	PSPC1-A	0.721558	5.92E-9	Positiv
	S2	379	2	e
MAP3K7	PSPC1-A	0.689889	4.91E-8	Positiv
	S2	65	1	e
CYLD	PSPC1-A	0.566010	3.61E-4	Positiv
	S2	716	9	e
IPMK	PSPC1-A	0.528207	6.46E-4	Positiv
	S2	11	2	e
BRAF	PSPC1-A	0.644774	1.04E-6	Positiv

	S2	658	7	e
CFLAR	PSPC1-A	0.624031	2.62E-6	Positiv
	S2	392	2	e
TSC1	AC01207	0.403544	1.54E-2	Positiv
	3.1	393	3	e
PANX1	WNT5A-	0.420025	1.48E-2	Positiv
	AS1	783	5	e
AXL	WNT5A-	0.458202	1.13E-3	Positiv
	AS1	929	0	e
KLF9	WNT5A-	0.422745	6.72E-2	Positiv
	AS1	387	6	e
SPATA2		0.442928	1.51E-2	Positiv
	SNHG17	4	8	e
MAPK8	AC07968	0.644166	1.52E-6	Positiv
	4.1	829	7	e
ATRX	AC07968	0.611641	2.84E-5	Positiv
	4.1	242	9	e
OTULIN	AC07968	0.731572	9.94E-9	Positiv
	4.1	134	6	e
MAP3K7	AC07968	0.558965	9.55E-4	Positiv
	4.1	076	8	e
BCL2L11	AC07968	0.444885	8.16E-2	Positiv
	4.1	899	9	e
CYLD	AC07968	0.601090	8.62E-5	Positiv
	4.1	912	7	e
FADD	AC07968	-0.42761	1.60E-2	Negati
	4.1	3874	6	ve
IPMK	AC07968	0.626890	4.98E-6	Positiv
	4.1	97	3	e
BRAF	AC07968	0.750093	3.52E-1	Positiv
	4.1	182	03	e

CFLAR	AC07968	0.586723	1.48E-5	Positiv
	4.1	323	3	e
MAPK8	AP00142	0.666581	7.37E-7	Positiv
	9.1	944	4	e
ATRX	AP00142	0.759577	2.97E-1	Positiv
	9.1	998	07	e
OTULIN	AP00142	0.809067	4.56E-1	Positiv
	9.1	912	32	e
MAP3K7	AP00142	0.609392	9.79E-5	Positiv
	9.1	67	9	e
BCL2L11	AP00142	0.473079	7.51E-3	Positiv
	9.1	669	3	e
CYLD	AP00142	0.718052	1.13E-9	Positiv
	9.1	916	0	e
IPMK	AP00142	0.651867	1.18E-6	Positiv
	9.1	229	9	e
KLF9	AP00142	0.453278	5.62E-3	Positiv
	9.1	456	0	e
BRAF	AP00142	0.836330	4.34E-1	Positiv
	9.1	953	49	e
CFLAR	AP00142	0.638609	4.63E-6	Positiv
	9.1	707	6	e
MAPK8	MIR100	0.511875	4.68E-3	Positiv
	HG	6	9	e
ATRX	MIR100	0.591694	1.17E-5	Positiv
	HG	877	4	e
OTULIN	MIR100	0.527492	8.68E-4	Positiv
	HG	359	2	e
MAP3K7	MIR100	0.504920	6.95E-3	Positiv
	HG	32	8	e
AXL	MIR100	0.479378	8.35E-3	Positiv

	HG	075	4	e
BCL2L11	MIR100	0.433415	2.81E-2	Positiv
	HG	851	7	e
CYLD	MIR100	0.691228	1.81E-8	Positiv
	HG	658	1	e
IPMK	MIR100	0.429841	8.24E-2	Positiv
	HG	641	7	e
KLF9	MIR100	0.653082	5.42E-7	Positiv
	HG	77	0	e
BRAF	MIR100	0.614885	4.70E-6	Positiv
	HG	196	0	e
CFLAR	MIR100	0.586767	1.44E-5	Positiv
	HG	884	3	e
TARDBP	AC09271	0.522090	7.93E-4	Positiv
	8.4	348	1	e
MAPK8	AC00425	0.486727	6.07E-3	Positiv
	3.1	527	5	e
ATRX	AC00425	0.536340	2.12E-4	Positiv
	3.1	171	3	e
OTULIN	AC00425	0.675321	1.79E-7	Positiv
	3.1	908	6	e
MAP3K7	AC00425	0.518864	2.92E-4	Positiv
	3.1	604	0	e
CYLD	AC00425	0.486432	6.75E-3	Positiv
	3.1	342	5	e
IPMK	AC00425	0.433999	2.36E-2	Positiv
	3.1	48	7	e
BRAF	AC00425	0.635547	2.95E-6	Positiv
	3.1	849	5	e
CFLAR	AC00425	0.579439	5.60E-5	Positiv
	3.1	982	2	e

MAPK8	AC02585	0.502378	1.84E-3	Positiv
	7.2	285	7	e
ATRX	AC02585	0.472578	8.93E-3	Positiv
	7.2	603	3	e
OTULIN	AC02585	0.589392	3.81E-5	Positiv
	7.2	498	4	e
CYLD	AC02585	0.512757	3.31E-3	Positiv
	7.2	04	9	e
IPMK	AC02585	0.454531	3.74E-3	Positiv
	7.2	899	0	e
BRAF	AC02585	0.564846	6.23E-4	Positiv
	7.2	797	9	e
CFLAR	AC02585	0.541746	2.08E-4	Positiv
	7.2	315	4	e
ATRX	AL16172	0.535595	2.91E-4	Positiv
	9.4	222	3	e
OTULIN	AL16172	0.428056	1.40E-2	Positiv
	9.4	303	6	e
MAP3K7	AL16172	0.433594	2.66E-2	Positiv
	9.4	667	7	e
TSC1	AL16172	0.464597	1.35E-3	Positiv
	9.4	439	1	e
BRAF	AL16172	0.533439	7.25E-4	Positiv
	9.4	95	3	e
MAPK8	AC09233	0.647780	1.58E-6	Positiv
	8.1	518	8	e
ATRX	AC09233	0.702464	3.38E-8	Positiv
	8.1	667	5	e
OTULIN	AC09233	0.824692	1.84E-1	Positiv
	8.1	253	41	e
MAP3K7	AC09233	0.666699	6.80E-7	Positiv

	8.1	631	4	e
BCL2L11	AC09233	0.449433	1.93E-2	Positiv
	8.1	771	9	e
CYLD	AC09233	0.677555	3.73E-7	Positiv
	8.1	276	7	e
IPMK	AC09233	0.582967	9.74E-5	Positiv
	8.1	025	3	e
KLF9	AC09233	0.416399	4.20E-2	Positiv
	8.1	715	5	e
BRAF	AC09233	0.825050	1.09E-1	Positiv
	8.1	097	41	e
CFLAR	AC09233	0.658337	1.79E-7	Positiv
	8.1	142	1	e
MAPK8	SCARN	0.657956	2.30E-7	Positiv
	A9	976	1	e
ATRX	SCARN	0.783428	2.15E-1	Positiv
	A9	391	18	e
OTULIN	SCARN	0.797240	1.63E-1	Positiv
	A9	067	25	e
MAP3K7	SCARN	0.616577	1.82E-6	Positiv
	A9	563	0	e
BCL2L11	SCARN	0.425520	2.98E-2	Positiv
	A9	312	6	e
CYLD	SCARN	0.707861	4.72E-8	Positiv
	A9	794	7	e
IPMK	SCARN	0.604313	1.54E-5	Positiv
	A9	562	7	e
KLF9	SCARN	0.416655	3.91E-2	Positiv
	A9	942	5	e
BRAF	SCARN	0.838177	2.36E-1	Positiv
	A9	214	50	e

CFLAR	SCARN	0.651714	1.30E-6	Positiv
	A9	381	9	e
ATRX	LINC018	0.510641	7.59E-3	Positiv
	76	655	9	e
BRAF	LINC018	0.511285	5.90E-3	Positiv
	76	469	9	e
CFLAR	LINC018	0.406903	6.09E-2	Positiv
	76	254	4	e
MAPK8	AC00006	0.533477	7.13E-4	Positiv
	1.1	537	3	e
ATRX	AC00006	0.640888	1.15E-6	Positiv
	1.1	4	6	e
OTULIN	AC00006	0.662057	1.53E-7	Positiv
	1.1	978	2	e
MAP3K7	AC00006	0.534079	5.53E-4	Positiv
	1.1	31	3	e
CYLD	AC00006	0.506833	3.33E-3	Positiv
	1.1	1	8	e
IPMK	AC00006	0.488643	3.03E-3	Positiv
	1.1	717	5	e
BRAF	AC00006	0.705333	3.53E-8	Positiv
	1.1	784	6	e
CFLAR	AC00006	0.471975	1.10E-3	Positiv
	1.1	206	2	e
TSC1	AL35707	0.433488	2.75E-2	Positiv
	9.1	917	7	e
MAPK8	AC02636	0.611866	2.51E-5	Positiv
	8.1	83	9	e
ATRX	AC02636	0.698162	9.48E-8	Positiv
	8.1	915	4	e
OTULIN	AC02636	0.750197	3.19E-1	Positiv

	8.1	173	03	e
MAP3K7	AC02636	0.583232	8.53E-5	Positiv
	8.1	521	3	e
BCL2L11	AC02636	0.452022	8.43E-3	Positiv
	8.1	061	0	e
CYLD	AC02636	0.620711	1.76E-6	Positiv
	8.1	17	1	e
FADD	AC02636	-0.41145	1.71E-2	Negati
	8.1	6772	4	ve
IPMK	AC02636	0.515643	1.06E-3	Positiv
	8.1	813	9	e
BRAF	AC02636	0.782815	4.33E-1	Positiv
	8.1	029	18	e
CFLAR	AC02636	0.641215	9.40E-6	Positiv
	8.1	481	7	e
MAPK8	ARHGE	0.541512	2.30E-4	Positiv
	F38-IT1	931	4	e
ATRX	ARHGE	0.606068	5.97E-5	Positiv
	F38-IT1	411	8	e
OTULIN	ARHGE	0.666949	5.75E-7	Positiv
	F38-IT1	026	4	e
MAP3K7	ARHGE	0.535818	2.65E-4	Positiv
	F38-IT1	549	3	e
CYLD	ARHGE	0.523722	4.08E-4	Positiv
	F38-IT1	818	1	e
IPMK	ARHGE	0.487958	3.89E-3	Positiv
	F38-IT1	031	5	e
BRAF	ARHGE	0.721226	7.84E-9	Positiv
	F38-IT1	962	2	e
CFLAR	ARHGE	0.538349	8.99E-4	Positiv
	F38-IT1	798	4	e

MAPK8	AC01584	0.587609	9.43E-5	Positiv
	9.3	461	4	e
ATRX	AC01584	0.652294	8.99E-7	Positiv
	9.3	133	0	e
OTULIN	AC01584	0.730652	2.25E-9	Positiv
	9.3	075	5	e
MAP3K7	AC01584	0.544306	6.82E-4	Positiv
	9.3	881	5	e
BCL2L11	AC01584	0.511234	6.02E-3	Positiv
	9.3	736	9	e
MPG	AC01584	-0.40952	2.93E-2	Negati
	9.3	9462	4	ve
TSC1	AC01584	0.558102	1.42E-4	Positiv
	9.3	256	7	e
CYLD	AC01584	0.614963	4.50E-6	Positiv
	9.3	887	0	e
IPMK	AC01584	0.511677	5.06E-3	Positiv
	9.3	413	9	e
BRAF	AC01584	0.777522	1.66E-1	Positiv
	9.3	914	15	e
CFLAR	AC01584	0.713551	4.71E-8	Positiv
	9.3	016	9	e
ATRX	PIK3IP1-	0.455250	2.96E-3	Positiv
	AS1	23	0	e
OTULIN	PIK3IP1-	0.415326	5.71E-2	Positiv
	AS1	78	5	e
BRAF	PIK3IP1-	0.495977	2.04E-3	Positiv
	AS1	375	6	e
CFLAR	PIK3IP1-	0.463899	1.70E-3	Positiv
	AS1	522	1	e
MAPK8	AL13611	0.629000	1.45E-6	Positiv

	5.2	66	3	e
ATRX	AL13611	0.656673	5.31E-7	Positiv
	5.2	963	1	e
OTULIN	AL13611	0.744649	6.36E-1	Positiv
	5.2	65	01	e
MAP3K7	AL13611	0.537525	1.28E-4	Positiv
	5.2	022	3	e
BCL2L11	AL13611	0.476000	2.73E-3	Positiv
	5.2	639	3	e
CYLD	AL13611	0.709062	1.80E-8	Positiv
	5.2	503	7	e
IPMK	AL13611	0.590961	1.71E-5	Positiv
	5.2	187	4	e
KLF9	AL13611	0.466365	7.44E-3	Positiv
	5.2	507	2	e
BRAF	AL13611	0.784498	6.30E-1	Positiv
	5.2	704	19	e
CFLAR	AL13611	0.626583	5.96E-6	Positiv
	5.2	647	3	e
ATRX	AC24588	0.521816	8.87E-4	Positiv
	4.8	379	1	e
OTULIN	AC24588	0.539102	6.51E-4	Positiv
	4.8	857	4	e
TSC1	AC24588	0.450876	1.22E-2	Positiv
	4.8	643	9	e
BRAF	AC24588	0.566499	2.86E-4	Positiv
	4.8	639	9	e
CFLAR	AC24588	0.485996	7.90E-3	Positiv
	4.8	023	5	e
ATRX	NCBP2-	0.512927	3.10E-3	Positiv
	AS1	458	9	e

OTULIN	NCBP2-	0.566274	3.18E-4	Positiv
	AS1	868	9	e
MAP3K7	NCBP2-	0.497366	1.22E-3	Positiv
	AS1	46	6	e
TSC1	NCBP2-	0.535628	2.87E-4	Positiv
	AS1	507	3	e
CYLD	NCBP2-	0.407451	5.23E-2	Positiv
	AS1	144	4	e
IPMK	NCBP2-	0.403254	1.66E-2	Positiv
	AS1	976	3	e
BRAF	NCBP2-	0.592130	9.36E-5	Positiv
	AS1	403	5	e
CFLAR	NCBP2-	0.544263	6.95E-4	Positiv
	AS1	064	5	e
KLF9	AC01592	0.413719	9.02E-2	Positiv
	2.2	631	5	e
ATRX	SNHG22	0.484522	1.34E-3	Positiv
		267	4	e
OTULIN	SNHG22	0.494364	3.71E-3	Positiv
		787	6	e
CYLD	SNHG22	0.447380	3.71E-2	Positiv
		673	9	e
BRAF	SNHG22	0.524326	3.19E-4	Positiv
		022	1	e
CFLAR	SNHG22	0.567477	1.80E-4	Positiv
		995	9	e
STUB1	AC11028	0.400199	3.82E-2	Positiv
	5.6	339	3	e
MPG	AC11028	0.435149	1.66E-2	Positiv
	5.6	527	7	e
MAPK8	AC00490	0.631608	3.11E-6	Positiv

	8.2	889	4	e
ATRX	AC00490	0.760044	1.85E-1	Positiv
	8.2	978	07	e
OTULIN	AC00490	0.711557	2.40E-8	Positiv
	8.2	867	8	e
MAP3K7	AC00490	0.622066	8.09E-6	Positiv
	8.2	933	2	e
BCL2L11	AC00490	0.404012	1.35E-2	Positiv
	8.2	248	3	e
CYLD	AC00490	0.626773	5.33E-6	Positiv
	8.2	308	3	e
FADD	AC00490	-0.43347	2.77E-2	Negati
	8.2	0837	7	ve
IPMK	AC00490	0.611651	2.83E-5	Positiv
	8.2	527	9	e
KLF9	AC00490	0.408684	3.71E-2	Positiv
	8.2	338	4	e
BRAF	AC00490	0.793041	2.71E-1	Positiv
	8.2	134	23	e
SIRT1	AC00490	0.422529	7.15E-2	Positiv
	8.2	384	6	e
CFLAR	AC00490	0.641931	6.05E-6	Positiv
	8.2	471	7	e
PANX1	AL13608	0.424361	4.18E-2	Positiv
	4.3	646	6	e
AXL	AL13608	0.432065	4.23E-2	Positiv
	4.3	885	7	e
KLF9	AL13608	0.435795	1.36E-2	Positiv
	4.3	757	7	e
ATRX	AL03455	0.536918	1.66E-4	Positiv
	0.1	791	3	e

OTULIN	AL03455	0.610884	4.32E-5	Positiv
	0.1	008	9	e
MAP3K7	AL03455	0.505831	4.90E-3	Positiv
	0.1	511	8	e
TSC1	AL03455	0.532570	1.05E-4	Positiv
	0.1	473	2	e
CYLD	AL03455	0.449007	2.21E-2	Positiv
	0.1	981	9	e
BRAF	AL03455	0.655788	9.44E-7	Positiv
	0.1	234	1	e
CFLAR	AL03455	0.635325	3.37E-6	Positiv
	0.1	812	5	e
MAPK8	AC14100	0.487819	4.09E-3	Positiv
	2.1	508	5	e
ATRX	AC14100	0.528382	6.00E-4	Positiv
	2.1	899	2	e
OTULIN	AC14100	0.592667	7.10E-5	Positiv
	2.1	727	5	e
MAP3K7	AC14100	0.464137	1.57E-3	Positiv
	2.1	708	1	e
BCL2L11	AC14100	0.450271	1.48E-2	Positiv
	2.1	07	9	e
TSC1	AC14100	0.530117	2.92E-4	Positiv
	2.1	197	2	e
CYLD	AC14100	0.471454	1.31E-3	Positiv
	2.1	15	2	e
BRAF	AC14100	0.642685	3.80E-6	Positiv
	2.1	155	7	e
CFLAR	AC14100	0.609312	1.02E-5	Positiv
	2.1	977	8	e
MYCN	AC00555	0.426540	2.20E-2	Positiv

	0.2	624	6	e
MAPK8	LINC018	0.517350	5.35E-4	Positiv
	11	145	0	e
ATRX	LINC018	0.689830	5.13E-8	Positiv
	11	878	1	e
OTULIN	LINC018	0.608455	1.63E-5	Positiv
	11	165	8	e
MAP3K7	LINC018	0.542339	1.61E-4	Positiv
	11	644	4	e
CYLD	LINC018	0.484698	1.26E-3	Positiv
	11	41	4	e
IPMK	LINC018	0.493865	4.47E-3	Positiv
	11	178	6	e
BRAF	LINC018	0.691029	2.10E-8	Positiv
	11	48	1	e
CFLAR	LINC018	0.467728	4.69E-3	Positiv
	11	326	2	e
CFLAR	AC09253	0.455954	2.36E-3	Positiv
	5.4	314	0	e
MAPK8	UBE2R2-	0.461233	4.15E-3	Positiv
	AS1	761	1	e
ATRX	UBE2R2-	0.520914	1.28E-4	Positiv
	AS1	529	0	e
OTULIN	UBE2R2-	0.608627	1.49E-5	Positiv
	AS1	772	8	e
BCL2L11	UBE2R2-	0.446755	4.53E-2	Positiv
	AS1	089	9	e
CYLD	UBE2R2-	0.515481	1.13E-3	Positiv
	AS1	809	9	e
BRAF	UBE2R2-	0.643891	1.80E-6	Positiv
	AS1	605	7	e

CFLAR	UBE2R2-	0.579279	6.06E-5	Positiv
	AS1	074	2	e
MAPK8	AL13928	0.452121	8.16E-3	Positiv
	9.1	398	0	e
ATRX	AL13928	0.455720	2.54E-3	Positiv
	9.1	73	0	e
OTULIN	AL13928	0.513155	2.83E-3	Positiv
	9.1	392	9	e
BCL2L11	AL13928	0.436841	9.91E-2	Positiv
	9.1	296	8	e
TSC1	AL13928	0.405669	8.56E-2	Positiv
	9.1	267	4	e
CYLD	AL13928	0.516923	6.35E-4	Positiv
	9.1	451	0	e
BRAF	AL13928	0.578520	8.81E-5	Positiv
	9.1	043	2	e
CFLAR	AL13928	0.609637	8.56E-5	Positiv
	9.1	377	9	e
MAPK8	MIR222	0.607656	2.52E-5	Positiv
	HG	432	8	e
ATRX	MIR222	0.721497	6.23E-9	Positiv
	HG	277	2	e
OTULIN	MIR222	0.750013	3.81E-1	Positiv
	HG	288	03	e
MAP3K7	MIR222	0.562103	2.24E-4	Positiv
	HG	432	8	e
BCL2L11	MIR222	0.416004	4.71E-2	Positiv
	HG	731	5	e
CYLD	MIR222	0.616410	2.00E-6	Positiv
	HG	942	0	e
IPMK	MIR222	0.563402	1.22E-4	Positiv

	HG	696	8	e
BRAF	MIR222	0.749048	9.65E-1	Positiv
	HG	306	03	e
CFLAR	MIR222	0.648821	8.20E-6	Positiv
	HG	219	9	e
MAPK8	AC09373	0.404103	1.32E-2	Positiv
	2.1	037	3	e
OTULIN	AC09373	0.480645	5.34E-3	Positiv
	2.1	256	4	e
BCL2L11	AC09373	0.492334	7.86E-3	Positiv
	2.1	092	6	e
TSC1	AC09373	0.503395	1.25E-3	Positiv
	2.1	303	7	e
CYLD	AC09373	0.470442	1.86E-3	Positiv
	2.1	652	2	e
BRAF	AC09373	0.531862	1.41E-4	Positiv
	2.1	367	2	e
CFLAR	AC09373	0.607082	3.45E-5	Positiv
	2.1	919	8	e
MAPK8	AC02635	0.635273	3.48E-6	Positiv
	6.1	281	5	e
ATRX	AC02635	0.740303	3.67E-9	Positiv
	6.1	194	9	e
OTULIN	AC02635	0.733948	1.19E-9	Positiv
	6.1	989	6	e
MAP3K7	AC02635	0.624921	1.56E-6	Positiv
	6.1	77	2	e
BCL2L11	AC02635	0.507621	2.46E-3	Positiv
	6.1	594	8	e
CYLD	AC02635	0.680074	6.23E-7	Positiv
	6.1	834	8	e

IPMK	AC02635	0.621716	9.89E-6	Positiv
	6.1	522	2	e
KLF9	AC02635	0.487093	5.31E-3	Positiv
	6.1	332	5	e
BRAF	AC02635	0.769311	1.23E-1	Positiv
	6.1	396	11	e
SIRT1	AC02635	0.471806	1.16E-3	Positiv
	6.1	728	2	e
CFLAR	AC02635	0.665908	1.16E-7	Positiv
	6.1	737	3	e
MAPK8	AC09105	0.630074	7.70E-6	Positiv
	7.4	488	4	e
ATRX	AC09105	0.703926	1.07E-8	Positiv
	7.4	475	5	e
OTULIN	AC09105	0.775985	9.04E-1	Positiv
	7.4	677	15	e
MAP3K7	AC09105	0.575110	4.66E-5	Positiv
	7.4	458	1	e
BCL2L11	AC09105	0.431296	5.33E-2	Positiv
	7.4	171	7	e
CYLD	AC09105	0.657854	2.46E-7	Positiv
	7.4	343	1	e
IPMK	AC09105	0.656922	4.51E-7	Positiv
	7.4	588	1	e
KLF9	AC09105	0.400116	3.90E-2	Positiv
	7.4	199	3	e
BRAF	AC09105	0.757743	1.88E-1	Positiv
	7.4	782	06	e
CFLAR	AC09105	0.602988	3.13E-5	Positiv
	7.4	951	7	e
DNMT1	B4GALT	-0.40270	1.93E-2	Negati

	1-AS1	7422	3	ve
TRAF2		0.432935	3.25E-2	Positiv
	SNHG7	311	7	e
TSC1	AP00236	0.422973	6.28E-2	Positiv
	0.3	148	6	e
MAPK8	AL16272	0.549935	5.68E-4	Positiv
	4.2	643	6	e
ATRX	AL16272	0.607573	2.64E-5	Positiv
	4.2	602	8	e
OTULIN	AL16272	0.658323	1.81E-7	Positiv
	4.2	184	1	e
MAP3K7	AL16272	0.489750	2.02E-3	Positiv
	4.2	474	5	e
BCL2L11	AL16272	0.486291	7.10E-3	Positiv
	4.2	498	5	e
TSC1	AL16272	0.476545	2.26E-3	Positiv
	4.2	841	3	e
CYLD	AL16272	0.573895	8.39E-5	Positiv
	4.2	145	1	e
IPMK	AL16272	0.440164	3.56E-2	Positiv
	4.2	995	8	e
BRAF	AL16272	0.700042	2.23E-8	Positiv
	4.2	353	4	e
CFLAR	AL16272	0.733381	1.98E-9	Positiv
	4.2	138	6	e
MAPK8	AC01880	0.474072	5.33E-3	Positiv
	9.1	944	3	e
ATRX	AC01880	0.641126	9.93E-6	Positiv
	9.1	258	7	e
OTULIN	AC01880	0.605221	9.44E-5	Positiv
	9.1	757	8	e

MAP3K7	AC01880	0.433410	2.82E-2	Positiv
	9.1	632	7	e
CYLD	AC01880	0.503617	1.14E-3	Positiv
	9.1	235	7	e
IPMK	AC01880	0.475165	3.65E-3	Positiv
	9.1	658	3	e
BRAF	AC01880	0.655645	1.04E-7	Positiv
	9.1	172	0	e
CFLAR	AC01880	0.555098	5.58E-4	Positiv
	9.1	452	7	e
MAPK8	SNHG16	0.493715	4.72E-3	Positiv
		718	6	e
ATRX	SNHG16	0.428051	1.41E-2	Positiv
		365	6	e
OTULIN	SNHG16	0.499535	5.38E-3	Positiv
		913	7	e
MAP3K7	SNHG16	0.403781	1.44E-2	Positiv
		652	3	e
BRAF	SNHG16	0.507273	2.81E-3	Positiv
		07	8	e
FAS	LINC018	0.406670	6.49E-2	Positiv
		71	04	4
CD40	LINC018	0.410448	2.27E-2	Positiv
		71	155	4
MAPK8	MALAT	0.597324	6.29E-5	Positiv
		1	865	6
ATRX	MALAT	0.666977	5.64E-7	Positiv
		1	373	4
OTULIN	MALAT	0.712084	1.56E-8	Positiv
		1	466	8
MAP3K7	MALAT	0.503988	9.93E-3	Positiv

	1	531	8	e
BCL2L11	MALAT	0.484091	1.57E-3	Positiv
	1	068	4	e
CYLD	MALAT	0.641166	9.69E-6	Positiv
	1	184	7	e
IPMK	MALAT	0.512147	4.21E-3	Positiv
	1	105	9	e
KLF9	MALAT	0.408791	3.60E-2	Positiv
	1	454	4	e
BRAF	MALAT	0.755636	1.54E-1	Positiv
	1	906	05	e
CFLAR	MALAT	0.663556	5.64E-7	Positiv
	1	938	3	e
ATRX	AC07886	0.458608	9.87E-3	Positiv
	0.1	62	1	e
OTULIN	AC07886	0.401269	2.85E-2	Positiv
	0.1	988	3	e
BRAF	AC07886	0.409411	3.03E-2	Positiv
	0.1	405	4	e
TNFRSF21	AL51227	0.411121	1.88E-2	Positiv
	4.1	121	4	e
MAPK8	AC09216	0.613465	1.04E-5	Positiv
	8.2	454	9	e
ATRX	AC09216	0.707082	8.81E-8	Positiv
	8.2	065	7	e
OTULIN	AC09216	0.790767	4.13E-1	Positiv
	8.2	072	22	e
MAP3K7	AC09216	0.623292	4.00E-6	Positiv
	8.2	302	2	e
BCL2L11	AC09216	0.484501	1.35E-3	Positiv
	8.2	3	4	e

TSC1	AC09216	0.404301	1.25E-2	Positiv
	8.2	582	3	e
CYLD	AC09216	0.641958	5.95E-6	Positiv
	8.2	842	7	e
IPMK	AC09216	0.526770	1.17E-4	Positiv
	8.2	377	1	e
KLF9	AC09216	0.407801	4.74E-2	Positiv
	8.2	591	4	e
BRAF	AC09216	0.786293	7.92E-1	Positiv
	8.2	716	20	e
CFLAR	AC09216	0.735908	2.04E-9	Positiv
	8.2	903	7	e
MAPK8	LINC025	0.573658	9.41E-5	Positiv
	95	178	1	e
ATRX	LINC025	0.757691	1.98E-1	Positiv
	95	682	06	e
OTULIN	LINC025	0.753808	9.39E-1	Positiv
	95	911	05	e
MAP3K7	LINC025	0.599437	2.07E-5	Positiv
	95	622	6	e
CYLD	LINC025	0.593007	5.95E-5	Positiv
	95	886	5	e
IPMK	LINC025	0.499895	4.70E-3	Positiv
	95	231	7	e
BRAF	LINC025	0.727204	4.62E-9	Positiv
	95	62	4	e
CFLAR	LINC025	0.605929	6.44E-5	Positiv
	95	265	8	e
CFLAR	LINC017	0.407712	4.86E-2	Positiv
	30	272	4	e
MAPK8	MIR181	0.585724	2.45E-5	Positiv

	A2HG	004	3	e
ATRX	MIR181	0.668419	2.11E-7	Positiv
	A2HG	343	4	e
OTULIN	MIR181	0.727442	3.76E-9	Positiv
	A2HG	238	4	e
MAP3K7	MIR181	0.589385	3.82E-5	Positiv
	A2HG	722	4	e
BCL2L11	MIR181	0.410232	2.41E-2	Positiv
	A2HG	298	4	e
CYLD	MIR181	0.581314	2.22E-5	Positiv
	A2HG	864	2	e
IPMK	MIR181	0.529310	4.08E-4	Positiv
	A2HG	36	2	e
BRAF	MIR181	0.734016	1.12E-9	Positiv
	A2HG	375	6	e
CFLAR	MIR181	0.620129	2.45E-6	Positiv
	A2HG	35	1	e
ATRX	AL35499	0.619541	3.42E-6	Positiv
	3.2	124	1	e
OTULIN	AL35499	0.416427	4.17E-2	Positiv
	3.2	117	5	e
MAP3K7	AL35499	0.483916	1.67E-3	Positiv
	3.2	084	4	e
IPMK	AL35499	0.401803	2.47E-2	Positiv
	3.2	88	3	e
BRAF	AL35499	0.517867	4.35E-4	Positiv
	3.2	539	0	e
CFLAR	AL35499	0.541965	1.89E-4	Positiv
	3.2	69	4	e
CFLAR	AC13045	0.403834	1.42E-2	Positiv
	6.3	059	3	e

	ARHGA				
TSC1	P27P1-B	0.498327	8.48E-3	Positiv	
	PTFP1-K	98	7	e	
	PNA2P3				
	ARHGA				
CFLAR	P27P1-B	0.412747	1.19E-2	Positiv	
	PTFP1-K	995	4	e	
	PNA2P3				
OTULIN	SNHG4	0.516324	8.06E-4	Positiv	
		209	0	e	
MAP3K7	SNHG4	0.456467	1.99E-3	Positiv	
		831	0	e	
TSC1	SNHG4	0.441933	2.06E-2	Positiv	
		638	8	e	
BRAF	SNHG4	0.494479	3.56E-3	Positiv	
		913	6	e	
CFLAR	SNHG4	0.405036	1.02E-2	Positiv	
		919	3	e	
PANX1	LINC012	0.417318	3.23E-2	Positiv	
	35	851	5	e	
KLF9	LINC012	0.498673	7.45E-3	Positiv	
	35	05	7	e	
MAP3K7	PAN3-A	0.438671	5.65E-2	Positiv	
	S1	867	8	e	
MAPK8	ALG13-	0.640893	1.15E-6	Positiv	
	AS1	464	6	e	
ATRX	ALG13-	0.839012	6.24E-1	Positiv	
	AS1	599	51	e	
OTULIN	ALG13-	0.746674	9.36E-1	Positiv	
	AS1	271	02	e	
MAP3K7	ALG13-	0.624784	1.69E-6	Positiv	

	AS1	389	2	e
BCL2L11	ALG13-	0.413007	1.10E-2	Positiv
	AS1	616	4	e
CYLD	ALG13-	0.662726	9.82E-7	Positiv
	AS1	555	3	e
IPMK	ALG13-	0.627550	3.39E-6	Positiv
	AS1	268	3	e
KLF9	ALG13-	0.401511	2.67E-2	Positiv
	AS1	762	3	e
BRAF	ALG13-	0.823023	2.05E-1	Positiv
	AS1	433	40	e
CFLAR	ALG13-	0.653204	5.01E-7	Positiv
	AS1	561	0	e
MAPK8	AL36527	0.645241	7.77E-6	Positiv
	7.1	25	8	e
ATRX	AL36527	0.677496	3.88E-7	Positiv
	7.1	809	7	e
OTULIN	AL36527	0.789222	2.57E-1	Positiv
	7.1	698	21	e
MAP3K7	AL36527		1.47E-6	Positiv
	7.1	0.616963	0	e
BCL2L11	AL36527	0.460636	5.05E-3	Positiv
	7.1	001	1	e
TSC1	AL36527	0.416777	3.77E-2	Positiv
	7.1	242	5	e
CYLD	AL36527	0.655308	1.29E-7	Positiv
	7.1	481	0	e
IPMK	AL36527	0.588143	7.20E-5	Positiv
	7.1	145	4	e
BRAF	AL36527	0.817638	4.15E-1	Positiv
	7.1	069	37	e

CFLAR	AL36527	0.668034	2.75E-7	Positiv
	7.1	948	4	e
TARDBP	AL03546	0.478572	1.11E-3	Positiv
	1.2	416	3	e
MAPK8	AC09885	0.547716	1.52E-4	Positiv
	1.1	312	5	e
ATRX	AC09885	0.618318	6.83E-6	Positiv
	1.1	429	1	e
OTULIN	AC09885	0.700253	1.89E-8	Positiv
	1.1	767	4	e
MAP3K7	AC09885	0.561283	3.28E-4	Positiv
	1.1	164	8	e
BCL2L11	AC09885	0.490718	1.42E-3	Positiv
	1.1	15	5	e
TSC1	AC09885	0.499439	5.58E-3	Positiv
	1.1	75	7	e
CYLD	AC09885	0.592966	6.08E-5	Positiv
	1.1	974	5	e
IPMK	AC09885	0.474491	4.61E-3	Positiv
	1.1	054	3	e
BRAF	AC09885	0.745864	2.02E-1	Positiv
	1.1	453	01	e
CFLAR	AC09885	0.714279	2.59E-8	Positiv
	1.1	258	9	e
ATRX	PRR7-AS	0.408160	4.29E-2	Positiv
	1	422	4	e
OTULIN	PRR7-AS	0.476459	2.32E-3	Positiv
	1	959	3	e
TSC1	PRR7-AS	0.461187	4.21E-3	Positiv
	1	774	1	e
BRAF	PRR7-AS	0.514310	1.79E-3	Positiv

	1	64	9	e	
CFLAR	PRR7-AS	0.483497	1.94E-3	Positiv	
	1	316	4	e	
MAPK8	DLEU2	0.620370	2.13E-6	Positiv	
		137	1	e	
ATRX	DLEU2	0.679965	6.73E-7	Positiv	
		51	8	e	
OTULIN	DLEU2	0.718413	8.39E-9	Positiv	
		229	1	e	
MAP3K7	DLEU2	0.704990	4.64E-8	Positiv	
		16	6	e	
BCL2L11	DLEU2	0.403977	1.36E-2	Positiv	
		391	3	e	
CYLD	DLEU2	0.612492	1.78E-5	Positiv	
		923	9	e	
IPMK	DLEU2	0.614139	7.12E-6	Positiv	
		191	0	e	
BRAF	DLEU2	0.698260	8.80E-8	Positiv	
		211	4	e	
SIRT1	DLEU2	0.425283	3.19E-2	Positiv	
		701	6	e	
CFLAR	DLEU2	0.663560	5.63E-7	Positiv	
		423	3	e	
OTULIN	AC12431	0.442626	1.66E-2	Positiv	
	9.1	89	8	e	
OTULIN	ABALO	0.462489	2.73E-3	Positiv	
	N	088	1	e	
MAP3K7	ABALO	0.401863	2.43E-2	Positiv	
	N	523	3	e	
BCL2L11	ABALO	0.412125	1.41E-2	Positiv	
	N	494	4	e	

BRAF	ABALO	0.427668	1.58E-2	Positiv
	N	71	6	e
CFLAR	ABALO	0.469499	2.57E-3	Positiv
	N	794	2	e
MAPK8	AC00212	0.564895	6.09E-4	Positiv
	8.2	111	9	e
ATRX	AC00212	0.643683	2.05E-6	Positiv
	8.2	904	7	e
OTULIN	AC00212	0.695724	6.11E-8	Positiv
	8.2	548	3	e
MAP3K7	AC00212	0.554007	9.14E-4	Positiv
	8.2	956	7	e
BCL2L11	AC00212	0.480592	5.44E-3	Positiv
	8.2	722	4	e
TSC1	AC00212	0.504517	8.11E-3	Positiv
	8.2	454	8	e
CYLD	AC00212	0.584307	4.98E-5	Positiv
	8.2	435	3	e
IPMK	AC00212	0.454798	3.43E-3	Positiv
	8.2	039	0	e
BRAF	AC00212	0.752542	3.25E-1	Positiv
	8.2	698	04	e
CFLAR	AC00212	0.742302	5.74E-1	Positiv
	8.2	716	00	e
MAP3K7	AC10081	0.470061	2.12E-3	Positiv
	4.1	94	2	e
KIAA1429	AC10081	0.428300	1.31E-2	Positiv
	4.1	302	6	e
IPMK	AC10081	0.430220	7.36E-2	Positiv
	4.1	375	7	e
BRAF	AC10081	0.406722	6.40E-2	Positiv

	4.1	797	4	e
MAPK8	CD44-A	0.628898	1.54E-6	Positiv
	S1	997	3	e
ATRX	CD44-A	0.660885	3.34E-7	Positiv
	S1	944	2	e
OTULIN	CD44-A	0.772966	2.43E-1	Positiv
	S1	209	13	e
MAP3K7	CD44-A	0.565768	4.04E-4	Positiv
	S1	732	9	e
BCL2L11	CD44-A	0.467775	4.62E-3	Positiv
	S1	226	2	e
CYLD	CD44-A	0.677808	3.12E-7	Positiv
	S1	251	7	e
IPMK	CD44-A	0.592213	8.97E-5	Positiv
	S1	984	5	e
KLF9	CD44-A	0.465551	9.79E-3	Positiv
	S1	466	2	e
BRAF	CD44-A	0.754004	7.75E-1	Positiv
	S1	099	05	e
CFLAR	CD44-A	0.663481	5.93E-7	Positiv
	S1	327	3	e
MAPK8	ANKRD	0.583106	9.09E-5	Positiv
	10-IT1	526	3	e
ATRX	ANKRD	0.694255	1.86E-8	Positiv
	10-IT1	366	2	e
OTULIN	ANKRD	0.726540	8.23E-9	Positiv
	10-IT1	435	4	e
MAP3K7	ANKRD	0.718300	9.22E-9	Positiv
	10-IT1	134	1	e
TSC1	ANKRD	0.402255	2.18E-2	Positiv
	10-IT1	075	3	e

CYLD	ANKRD	0.602824	3.42E-5	Positiv
	10-IT1	814	7	e
IPMK	ANKRD	0.590912	1.75E-5	Positiv
	10-IT1	059	4	e
KLF9	ANKRD	0.405601	8.72E-2	Positiv
	10-IT1	484	4	e
BRAF	ANKRD	0.710672	4.92E-8	Positiv
	10-IT1	459	8	e
CFLAR	ANKRD	0.683785	4.32E-7	Positiv
	10-IT1	15	9	e
MAPK8	AC00864	0.475080	3.76E-3	Positiv
	9.2	57	3	e
ATRX	AC00864	0.505310	5.99E-3	Positiv
	9.2	579	8	e
OTULIN	AC00864	0.585582	2.63E-5	Positiv
	9.2	926	3	e
MAP3K7	AC00864	0.426961	1.94E-2	Positiv
	9.2	01	6	e
BCL2L11	AC00864	0.461934	3.28E-3	Positiv
	9.2	39	1	e
TSC1	AC00864	0.460320	5.61E-3	Positiv
	9.2	422	1	e
CYLD	AC00864	0.502578	1.70E-3	Positiv
	9.2	061	7	e
BRAF	AC00864	0.644359	1.35E-6	Positiv
	9.2	272	7	e
CFLAR	AC00864	0.655695	1.00E-7	Positiv
	9.2	793	0	e
ATRX	AL35629	0.487969	3.87E-3	Positiv
	9.2	965	5	e
OTULIN	AL35629	0.553728	1.04E-4	Positiv

	9.2	44	6	e
MAP3K7	AL35629	0.440437	3.27E-2	Positiv
	9.2	338	8	e
BRAF	AL35629	0.540106	4.22E-4	Positiv
	9.2	138	4	e
CFLAR	AL35629	0.438367	6.20E-2	Positiv
	9.2	332	8	e
TRAF2	AL12183	0.426630	2.14E-2	Positiv
	2.2	981	6	e
SPATA2	AL12183	0.459099	8.40E-3	Positiv
	2.2	376	1	e
MAPK8	AC00887	0.526408	1.36E-4	Positiv
	0.2	377	1	e
ATRX	AC00887	0.611884	2.49E-5	Positiv
	0.2	374	9	e
OTULIN	AC00887	0.647233	2.23E-6	Positiv
	0.2	127	8	e
MAP3K7	AC00887	0.554265	8.14E-4	Positiv
	0.2	426	7	e
BCL2L11	AC00887	0.449540	1.87E-2	Positiv
	0.2	262	9	e
TSC1	AC00887	0.568554	1.08E-4	Positiv
	0.2	639	9	e
CYLD	AC00887	0.559959	6.04E-4	Positiv
	0.2	274	8	e
IPMK	AC00887	0.487959	3.88E-3	Positiv
	0.2	006	5	e
BRAF	AC00887	0.706853	1.06E-8	Positiv
	0.2	705	6	e
CFLAR	AC00887	0.656159	7.42E-7	Positiv
	0.2	711	1	e

MAPK8	AC00712	0.427707	1.56E-2	Positiv
	8.1	61	6	e
ATRX	AC00712	0.597091	7.11E-5	Positiv
	8.1	194	6	e
OTULIN	AC00712	0.493161	5.79E-3	Positiv
	8.1	577	6	e
MAP3K7	AC00712	0.583273	8.36E-5	Positiv
	8.1	783	3	e
KIAA1429	AC00712	0.412982	1.11E-2	Positiv
	8.1	086	4	e
CYLD	AC00712	0.432166	4.10E-2	Positiv
	8.1	024	7	e
IPMK	AC00712	0.473242	7.10E-3	Positiv
	8.1	959	3	e
BRAF	AC00712	0.576754	2.09E-5	Positiv
	8.1	695	1	e
SIRT1	AC00712	0.443690	1.19E-2	Positiv
	8.1	846	8	e
CFLAR	AC00712	0.506707	3.50E-3	Positiv
	8.1	549	8	e
MAPK8	AC05879	0.651019	2.03E-6	Positiv
	1.1	359	9	e
ATRX	AC05879	0.715402	1.03E-8	Positiv
	1.1	025	9	e
OTULIN	AC05879	0.758817	6.39E-1	Positiv
	1.1	869	07	e
MAP3K7	AC05879	0.559399	7.82E-4	Positiv
	1.1	3	8	e
BCL2L11	AC05879	0.482774	2.51E-3	Positiv
	1.1	044	4	e
CYLD	AC05879	0.675362	1.74E-7	Positiv

	1.1	969	6	e
IPMK	AC05879	0.608727	1.41E-5	Positiv
	1.1	382	8	e
BRAF	AC05879	0.844088	1.63E-1	Positiv
	1.1	207	54	e
CFLAR	AC05879	0.692315	8.02E-8	Positiv
	1.1	961	2	e
APP	AC00211	-0.41661	3.96E-2	Negati
	6.2	2853	5	ve
ATRX	LINC021	0.407738	4.83E-2	Positiv
	63	359	4	e
MAP3K7	LINC021	0.429948	7.98E-2	Positiv
	63	954	7	e
BRAF	LINC021	0.469324	2.73E-3	Positiv
	63	075	2	e
MYC	VPS9D1-	0.544169	7.24E-4	Positiv
	AS1	969	5	e
SPATA2	VPS9D1-	0.404873	1.07E-2	Positiv
	AS1	944	3	e
MAPK8	GABPB1	0.496401	1.74E-3	Positiv
	-AS1	649	6	e
ATRX	GABPB1	0.626139	7.72E-6	Positiv
	-AS1	321	3	e
OTULIN	GABPB1	0.655712	9.92E-7	Positiv
	-AS1	012	1	e
MAP3K7	GABPB1	0.556685	2.71E-4	Positiv
	-AS1	561	7	e
BCL2L11	GABPB1	0.409680	2.81E-2	Positiv
	-AS1	707	4	e
TSC1	GABPB1	0.433952	2.39E-2	Positiv
	-AS1	488	7	e

CYLD	GABPB1	0.520910	1.28E-4	Positiv
	-AS1	562	0	e
IPMK	GABPB1	0.449369	1.97E-2	Positiv
	-AS1	343	9	e
BRAF	GABPB1	0.658311	1.82E-7	Positiv
	-AS1	065	1	e
CFLAR	GABPB1	0.640174	1.78E-6	Positiv
	-AS1	096	6	e
MAPK8	Z68871.1	0.580201	3.85E-5	Positiv
		835	2	e
ATRX	Z68871.1	0.843546	3.99E-1	Positiv
		792	54	e
OTULIN	Z68871.1	0.699594	3.15E-8	Positiv
		614	4	e
MAP3K7	Z68871.1	0.631318	3.69E-6	Positiv
		955	4	e
CYLD	Z68871.1	0.617105	1.35E-6	Positiv
		763	0	e
IPMK	Z68871.1	0.545225	4.56E-4	Positiv
		762	5	e
BRAF	Z68871.1	0.789795	1.31E-1	Positiv
		876	21	e
CFLAR	Z68871.1	0.627525	3.44E-6	Positiv
		663	3	e
AXL	SERTAD	0.412156	1.40E-2	Positiv
	4-AS1	278	4	e
MAPK8	AC10359	0.563267	1.30E-4	Positiv
	1.3	892	8	e
ATRX	AC10359	0.640363	1.59E-6	Positiv
	1.3	582	6	e
OTULIN	AC10359	0.742483	4.85E-1	Positiv

	1.3	965	00	e
MAP3K7	AC10359	0.595865	1.35E-5	Positiv
	1.3	966	5	e
CYLD	AC10359	0.572415	1.71E-5	Positiv
	1.3	337	0	e
IPMK	AC10359	0.585247	3.11E-5	Positiv
	1.3	774	3	e
BRAF	AC10359	0.698666	6.43E-8	Positiv
	1.3	97	4	e
CFLAR	AC10359	0.531881	1.40E-4	Positiv
	1.3	213	2	e
TSC1	AC01146	0.415916	4.83E-2	Positiv
	2.4	892	5	e
MAPK8	AL35469	0.526760	1.17E-4	Positiv
	6.1	626	1	e
ATRX	AL35469	0.488637	3.04E-3	Positiv
	6.1	039	5	e
OTULIN	AL35469	0.520636	1.43E-4	Positiv
	6.1	124	0	e
MAP3K7	AL35469	0.619973	2.67E-6	Positiv
	6.1	353	1	e
CYLD	AL35469	0.422444	7.33E-2	Positiv
	6.1	721	6	e
IPMK	AL35469	0.480176	6.30E-3	Positiv
	6.1	9	4	e
BRAF	AL35469	0.520101	1.77E-4	Positiv
	6.1	133	0	e
CFLAR	AL35469	0.490306	1.65E-3	Positiv
	6.1	481	5	e
MAPK8	AC01639	0.476370	2.40E-3	Positiv
	4.1	284	3	e

ATRX	AC01639	0.575727	3.45E-5	Positiv
	4.1	768	1	e
OTULIN	AC01639	0.595313	1.80E-5	Positiv
	4.1	673	5	e
MAP3K7	AC01639	0.553426	1.19E-4	Positiv
	4.1	947	6	e
CYLD	AC01639	0.433278	2.93E-2	Positiv
	4.1	349	7	e
IPMK	AC01639	0.470550	1.79E-3	Positiv
	4.1	744	2	e
BRAF	AC01639	0.589284	4.03E-5	Positiv
	4.1	299	4	e
CFLAR	AC01639	0.493567	4.99E-3	Positiv
	4.1	594	6	e
ATRX	AC10682	0.420386	1.33E-2	Positiv
	0.3	53	5	e
OTULIN	AC10682	0.507822	2.27E-3	Positiv
	0.3	201	8	e
TSC1	AC10682	0.430276	7.24E-2	Positiv
	0.3	729	7	e
CYLD	AC10682	0.403051	1.76E-2	Positiv
	0.3	535	3	e
BRAF	AC10682	0.487342	4.86E-3	Positiv
	0.3	872	5	e
CFLAR	AC10682	0.522137	7.79E-4	Positiv
	0.3	202	1	e
MAPK8	AC04834	0.614599	5.51E-6	Positiv
	1.2	984	0	e
ATRX	AC04834	0.661482	2.25E-7	Positiv
	1.2	367	2	e
OTULIN	AC04834	0.761257	5.38E-1	Positiv

	1.2	307	08	e
MAP3K7	AC04834	0.653665	3.73E-7	Positiv
	1.2	124	0	e
BCL2L11	AC04834	0.477873	1.42E-3	Positiv
	1.2	186	3	e
TSC1	AC04834	0.422648	6.91E-2	Positiv
	1.2	773	6	e
CYLD	AC04834	0.651189	1.82E-6	Positiv
	1.2	915	9	e
IPMK	AC04834	0.576083	2.90E-5	Positiv
	1.2	334	1	e
KLF9	AC04834	0.432999	3.19E-2	Positiv
	1.2	864	7	e
BRAF	AC04834	0.753720	1.02E-1	Positiv
	1.2	538	04	e
CFLAR	AC04834	0.707113	8.59E-8	Positiv
	1.2	798	7	e
MAPK8	NEAT1	0.597517	5.69E-5	Positiv
		393	6	e
ATRX	NEAT1	0.649126	6.76E-6	Positiv
		004	9	e
OTULIN	NEAT1	0.745824	2.10E-1	Positiv
		012	01	e
MAP3K7	NEAT1	0.559658	6.94E-4	Positiv
		64	8	e
BCL2L11	NEAT1	0.518710	3.11E-4	Positiv
		669	0	e
CYLD	NEAT1	0.664238	3.57E-7	Positiv
		035	3	e
IPMK	NEAT1	0.528902	4.84E-4	Positiv
		174	2	e

KLF9	NEAT1	0.462108	3.10E-3	Positiv
		231	1	e
BRAF	NEAT1	0.750142	3.36E-1	Positiv
		653	03	e
CFLAR	NEAT1	0.730396	2.81E-9	Positiv
		945	5	e
TSC1	AP00662	0.616284	2.15E-6	Positiv
		1.2	78	0
BRAF	AP00662	0.452974	6.20E-3	Positiv
		1.2	568	0
CFLAR	AP00662	0.518871	2.91E-4	Positiv
		1.2	981	0
MAPK8	LINC014	0.610742	4.67E-5	Positiv
		73	7	9
ATRX	LINC014	0.771968	7.15E-1	Positiv
		73	054	13
OTULIN	LINC014	0.694821	1.21E-8	Positiv
		73	422	2
MAP3K7	LINC014	0.666240	9.28E-7	Positiv
		73	286	4
CYLD	LINC014	0.593450	4.74E-5	Positiv
		73	936	5
IPMK	LINC014	0.627797	2.93E-6	Positiv
		73	797	3
BRAF	LINC014	0.775892	1.00E-1	Positiv
		73	555	14
SIRT1	LINC014	0.404838	1.08E-2	Positiv
		73	176	3
CFLAR	LINC014	0.631003	4.45E-6	Positiv
		73	114	4
MAPK8	AL03198	0.465963	8.52E-3	Positiv

	5.3	557	2	e
ATRX	AL03198	0.533025	8.63E-4	Positiv
	5.3	216	3	e
OTULIN	AL03198	0.441597	2.28E-2	Positiv
	5.3	016	8	e
STUB1	AL03198	-0.43029	7.19E-2	Negati
	5.3	7348	7	ve
IPMK	AL03198	0.439338	4.60E-2	Positiv
	5.3	335	8	e
BRAF	AL03198	0.519152	2.60E-4	Positiv
	5.3	766	0	e
CFLAR	AL03198	0.409110	3.30E-2	Positiv
	5.3	701	4	e
MAPK8	AL13896	0.647697	1.67E-6	Positiv
	3.1	023	8	e
ATRX	AL13896	0.748504	1.63E-1	Positiv
	3.1	817	02	e
OTULIN	AL13896	0.761202	5.69E-1	Positiv
	3.1	57	08	e
MAP3K7	AL13896	0.666084	1.03E-7	Positiv
	3.1	892	3	e
BCL2L11	AL13896	0.426955	1.95E-2	Positiv
	3.1	658	6	e
CYLD	AL13896	0.672208	1.57E-7	Positiv
	3.1	609	5	e
IPMK	AL13896	0.629200	1.29E-6	Positiv
	3.1	367	3	e
KLF9	AL13896	0.440632	3.08E-2	Positiv
	3.1	399	8	e
BRAF	AL13896	0.808554	8.98E-1	Positiv
	3.1	215	32	e

CFLAR	AL13896	0.714817	1.66E-8	Positiv
	3.1	28	9	e
MAPK8	AC02215	0.630254	6.93E-6	Positiv
	0.4	044	4	e
ATRX	AC02215	0.602675	3.70E-5	Positiv
	0.4	785	7	e
OTULIN	AC02215	0.774159	6.66E-1	Positiv
	0.4	805	14	e
MAP3K7	AC02215	0.580943	2.66E-5	Positiv
	0.4	615	2	e
BCL2L11	AC02215	0.446082	5.60E-2	Positiv
	0.4	984	9	e
CYLD	AC02215	0.686628	5.44E-8	Positiv
	0.4	057	0	e
IPMK	AC02215	0.535900	2.56E-4	Positiv
	0.4	048	3	e
KLF9	AC02215	0.414265	7.72E-2	Positiv
	0.4	39	5	e
BRAF	AC02215	0.739706	6.36E-9	Positiv
	0.4	338	9	e
CFLAR	AC02215	0.656336	6.61E-7	Positiv
	0.4	676	1	e
MAPK8	AC13197	0.679025	1.32E-7	Positiv
	1.1	045	7	e
ATRX	AC13197	0.727788	2.78E-9	Positiv
	1.1	8	4	e
OTULIN	AC13197	0.848486	1.01E-1	Positiv
	1.1	578	57	e
MAP3K7	AC13197	0.639027	3.59E-6	Positiv
	1.1	042	6	e
BCL2L11	AC13197	0.495361	2.57E-3	Positiv

	1.1	502	6	e
CYLD	AC13197	0.720992	9.56E-9	Positiv
	1.1	081	2	e
IPMK	AC13197	0.632743	1.58E-6	Positiv
	1.1	462	4	e
KLF9	AC13197	0.438033	6.87E-2	Positiv
	1.1	517	8	e
BRAF	AC13197	0.844399	9.75E-1	Positiv
	1.1	679	55	e
CFLAR	AC13197	0.682566	1.04E-7	Positiv
	1.1	688	8	e
MAPK8	ZNF433-	0.600215	1.37E-5	Positiv
	AS1	338	6	e
ATRX	ZNF433-	0.560988	3.76E-4	Positiv
	AS1	349	8	e
OTULIN	ZNF433-	0.654933	1.64E-7	Positiv
	AS1	202	0	e
MAP3K7	ZNF433-	0.566446	2.94E-4	Positiv
	AS1	387	9	e
CYLD	ZNF433-	0.536761	1.77E-4	Positiv
	AS1	629	3	e
IPMK	ZNF433-	0.510685	7.46E-3	Positiv
	AS1	642	9	e
BRAF	ZNF433-	0.605271	9.19E-5	Positiv
	AS1	502	8	e
CFLAR	ZNF433-	0.543880	8.21E-4	Positiv
	AS1	761	5	e
SPATA2	LINC002	0.419622	1.66E-2	Positiv
	65	322	5	e
CYLD	LINC023	0.459885	6.48E-3	Positiv
	62	828	1	e

CFLAR	LINC023	0.499293	5.90E-3	Positiv
	62	549	7	e
MAPK8	AC02091	0.485712	8.74E-3	Positiv
	5.2	764	5	e
ATRX	AC02091	0.541133	2.71E-4	Positiv
	5.2	977	4	e
OTULIN	AC02091	0.618447	6.35E-6	Positiv
	5.2	441	1	e
MAP3K7	AC02091	0.456866	1.75E-3	Positiv
	5.2	015	0	e
BCL2L11	AC02091	0.467197	5.61E-3	Positiv
	5.2	533	2	e
TSC1	AC02091	0.492581	7.17E-3	Positiv
	5.2	86	6	e
CYLD	AC02091	0.512628	3.48E-3	Positiv
	5.2	574	9	e
BRAF	AC02091	0.663430	6.14E-7	Positiv
	5.2	993	3	e
CFLAR	AC02091	0.706903	1.02E-8	Positiv
	5.2	612	6	e
OTULIN	PVT1	0.421603	9.37E-2	Positiv
		557	6	e
KIAA1429	PVT1	0.450983	1.18E-2	Positiv
		933	9	e
BRAF	PVT1	0.403087	1.74E-2	Positiv
		584	3	e
MAPK8	AC01146	0.527169	9.92E-4	Positiv
	8.1	259	2	e
ATRX	AC01146	0.755446	1.86E-1	Positiv
	8.1	833	05	e
OTULIN	AC01146	0.640362	1.59E-6	Positiv

	8.1	884	6	e
MAP3K7	AC01146	0.564674	6.75E-4	Positiv
	8.1	409	9	e
CYLD	AC01146	0.542158	1.74E-4	Positiv
	8.1	493	4	e
IPMK	AC01146	0.474823	4.11E-3	Positiv
	8.1	896	3	e
BRAF	AC01146	0.711247	3.09E-8	Positiv
	8.1	055	8	e
CFLAR	AC01146	0.542707	1.37E-4	Positiv
	8.1	697	4	e
MAPK8	AC24396	0.498331	8.46E-3	Positiv
	7.2	684	7	e
ATRX	AC24396	0.606453	4.85E-5	Positiv
	7.2	228	8	e
OTULIN	AC24396	0.605723	7.20E-5	Positiv
	7.2	625	8	e
MAP3K7	AC24396	0.501636	2.43E-3	Positiv
	7.2	203	7	e
CYLD	AC24396	0.490020	1.83E-3	Positiv
	7.2	285	5	e
IPMK	AC24396	0.463446	1.98E-3	Positiv
	7.2	83	1	e
BRAF	AC24396	0.629502	1.08E-6	Positiv
	7.2	628	3	e
CFLAR	AC24396	0.577010	1.84E-5	Positiv
	7.2	711	1	e
MAPK8	AP00069	0.540583	3.44E-4	Positiv
	2.1	921	4	e
ATRX	AP00069	0.634163	6.78E-6	Positiv
	2.1	385	5	e

OTULIN	AP00069	0.660303	4.91E-7	Positiv
	2.1	507	2	e
MAP3K7	AP00069	0.475377	3.39E-3	Positiv
	2.1	893	3	e
BCL2L11	AP00069	0.463130	2.20E-3	Positiv
	2.1	904	1	e
CYLD	AP00069	0.640561	1.40E-6	Positiv
	2.1	931	6	e
FADD	AP00069	-0.41257	1.25E-2	Negati
	2.1	0426	4	ve
IPMK	AP00069	0.492983	6.19E-3	Positiv
	2.1	496	6	e
KLF9	AP00069	0.449042	2.19E-2	Positiv
	2.1	268	9	e
BRAF	AP00069	0.718268	9.47E-9	Positiv
	2.1	596	1	e
CFLAR	AP00069	0.644664	1.11E-6	Positiv
	2.1	567	7	e
MAPK8	AC00483	0.466740	6.55E-3	Positiv
	7.2	859	2	e
ATRX	AC00483	0.550249	4.94E-4	Positiv
	7.2	669	6	e
OTULIN	AC00483	0.604104	1.72E-5	Positiv
	7.2	49	7	e
MAP3K7	AC00483	0.510394	8.36E-3	Positiv
	7.2	626	9	e
CYLD	AC00483	0.476767	2.09E-3	Positiv
	7.2	698	3	e
IPMK	AC00483	0.446786	4.48E-2	Positiv
	7.2	533	9	e
BRAF	AC00483	0.649099	6.88E-6	Positiv

	7.2	136	9	e
CFLAR	AC00483	0.547761	1.49E-4	Positiv
	7.2	91	5	e
TSC1	AC14520	0.537045	1.57E-4	Positiv
	7.8	865	3	e
BRAF	AC14520	0.420026	1.48E-2	Positiv
	7.8	442	5	e
CFLAR	AC14520	0.452610	6.97E-3	Positiv
	7.8	535	0	e
AXL	SMIM25	0.447051	4.12E-2	Positiv
		805	9	e
TNF	SMIM25	0.426791	2.04E-2	Positiv
		735	6	e
ATRX	AC09011	0.534454	4.72E-4	Positiv
	6.1	535	3	e
OTULIN	AC09011	0.448948	2.26E-2	Positiv
	6.1	083	9	e
BRAF	AC09011	0.457171	1.58E-3	Positiv
	6.1	639	0	e
MAPK8	CASC19	0.496568	1.64E-3	Positiv
		685	6	e
ATRX	CASC19	0.586611	1.56E-5	Positiv
		03	3	e
OTULIN	CASC19	0.650039	3.79E-6	Positiv
		81	9	e
MAP3K7	CASC19	0.538059	1.02E-4	Positiv
		377	3	e
CYLD	CASC19	0.436303	1.17E-2	Positiv
		3	7	e
IPMK	CASC19	0.480565	5.49E-3	Positiv
		705	4	e

BRAF	CASC19	0.616426	1.98E-6	Positiv
		92	0	e
CFLAR	CASC19	0.467192	5.62E-3	Positiv
		11	2	e
ATRX	AL03507	0.419337	1.81E-2	Positiv
	1.1	361	5	e
OTULIN	AL03507	0.479176	8.96E-3	Positiv
	1.1	491	4	e
MAP3K7	AL03507	0.482513	2.75E-3	Positiv
	1.1	72	4	e
IPMK	AL03507	0.400771	3.27E-2	Positiv
	1.1	725	3	e
BRAF	AL03507	0.514484	1.67E-3	Positiv
	1.1	303	9	e
AXL	LINC023	0.526519	1.30E-4	Positiv
	81	432	1	e
GATA3	LINC023	0.409837	2.69E-2	Positiv
	81	841	4	e
KLF9	LINC023	0.427242	1.79E-2	Positiv
	81	262	6	e
MAPK8	AL15783	0.563127	1.39E-4	Positiv
	8.1	355	8	e
ATRX	AL15783	0.693255	3.96E-8	Positiv
	8.1	315	2	e
OTULIN	AL15783	0.711647	2.23E-8	Positiv
	8.1	499	8	e
MAP3K7	AL15783	0.604755	1.21E-5	Positiv
	8.1	082	7	e
BCL2L11	AL15783	0.488006	3.82E-3	Positiv
	8.1	68	5	e
TSC1	AL15783	0.484147	1.53E-3	Positiv

	8.1	206	4	e
CYLD	AL15783	0.605134	9.89E-5	Positiv
	8.1	844	8	e
IPMK	AL15783	0.486957	5.58E-3	Positiv
	8.1	39	5	e
KLF9	AL15783	0.405477	9.03E-2	Positiv
	8.1	66	4	e
BRAF	AL15783	0.747566	4.00E-1	Positiv
	8.1	846	02	e
CFLAR	AL15783	0.767204	1.14E-1	Positiv
	8.1	808	10	e
MAPK8	LINC011	0.403301	1.64E-2	Positiv
	38	411	3	e
ATRX	LINC011	0.514627	1.58E-3	Positiv
	38	136	9	e
OTULIN	LINC011	0.487284	4.96E-3	Positiv
	38	132	5	e
MAP3K7	LINC011	0.478295	1.22E-3	Positiv
	38	46	3	e
TSC1	LINC011	0.401179	2.93E-2	Positiv
	38	361	3	e
CYLD	LINC011	0.469785	2.33E-3	Positiv
	38	749	2	e
BRAF	LINC011	0.535279	3.33E-4	Positiv
	38	032	3	e
CFLAR	LINC011	0.637815	7.50E-6	Positiv
	38	636	6	e
MAPK8	AC06203	0.506998	3.12E-3	Positiv
	7.2	892	8	e
ATRX	AC06203	0.594600	2.61E-5	Positiv
	7.2	45	5	e

OTULIN	AC06203	0.549827	5.96E-4	Positiv
	7.2	412	6	e
MAP3K7	AC06203	0.480503	5.61E-3	Positiv
	7.2	134	4	e
BCL2L11	AC06203	0.453705	4.89E-3	Positiv
	7.2	103	0	e
CYLD	AC06203	0.575403	4.04E-5	Positiv
	7.2	522	1	e
IPMK	AC06203	0.461947	3.27E-3	Positiv
	7.2	972	1	e
BRAF	AC06203	0.628108	2.45E-6	Positiv
	7.2	602	3	e
CFLAR	AC06203	0.629554	1.05E-6	Positiv
	7.2	86	3	e
MAPK8	AL44206	0.598536	3.33E-5	Positiv
	7.1	856	6	e
ATRX	AL44206	0.637408	9.60E-6	Positiv
	7.1	209	6	e
OTULIN	AL44206	0.772947	2.49E-1	Positiv
	7.1	163	13	e
MAP3K7	AL44206	0.647172	2.32E-6	Positiv
	7.1	977	8	e
BCL2L11	AL44206	0.468859	3.19E-3	Positiv
	7.1	048	2	e
CYLD	AL44206	0.627947	2.69E-6	Positiv
	7.1	776	3	e
IPMK	AL44206	0.517686	4.68E-4	Positiv
	7.1	448	0	e
KLF9	AL44206	0.445429	6.88E-2	Positiv
	7.1	803	9	e
BRAF	AL44206	0.706863	1.05E-8	Positiv

	7.1	866	6	e
CFLAR	AL44206	0.678297	2.20E-7	Positiv
	7.1	016	7	e
TRAF2	AL02170	0.424042	4.59E-2	Positiv
	7.6	634	6	e
MAPK8	AC00424	0.619776	2.99E-6	Positiv
	1.3	56	1	e
ATRX	AC00424	0.475651	3.08E-3	Positiv
	1.3	093	3	e
DIABLO	AC00424	0.416510	4.07E-2	Positiv
	1.3	794	5	e
OTULIN	AC00424	0.617061	1.39E-6	Positiv
	1.3	108	0	e
MAP3K7	AC00424	0.488702	2.97E-3	Positiv
	1.3	362	5	e
CYLD	AC00424	0.518636	3.20E-4	Positiv
	1.3	899	0	e
IPMK	AC00424	0.559767	6.60E-4	Positiv
	1.3	713	8	e
BRAF	AC00424	0.562498	1.86E-4	Positiv
	1.3	636	8	e
MAPK8	AC00012	0.624162	2.43E-6	Positiv
	3.1	06	2	e
ATRX	AC00012	0.780710	4.70E-1	Positiv
	3.1	489	17	e
OTULIN	AC00012	0.784604	5.58E-1	Positiv
	3.1	426	19	e
STUB1	AC00012	-0.41296	1.12E-2	Negati
	3.1	4746	4	ve
MAP3K7	AC00012	0.694446	1.61E-8	Positiv
	3.1	67	2	e

TSC1	AC00012	0.410430	2.28E-2	Positiv
	3.1	292	4	e
CYLD	AC00012	0.635303	3.42E-6	Positiv
	3.1	27	5	e
FADD	AC00012	-0.42640	2.29E-2	Negati
	3.1	4845	6	ve
IPMK	AC00012	0.626192	7.48E-6	Positiv
	3.1	863	3	e
BRAF	AC00012	0.847764	3.45E-1	Positiv
	3.1	159	57	e
CFLAR	AC00012	0.670920	3.81E-7	Positiv
	3.1	505	5	e
HAT1	AC09985	0.471303	1.38E-3	Positiv
	0.3	693	2	e
TARDBP	AC09985	0.428055	1.40E-2	Positiv
	0.3	462	6	e
MAP3K7	AC09985	0.403888	1.40E-2	Positiv
	0.3	594	3	e
CASP8	AC09985	0.470012	2.15E-3	Positiv
	0.3	237	2	e
TARDBP	AC02640	0.433657	2.61E-2	Positiv
	1.3	212	7	e
TSC1	AC25353	0.412588	1.24E-2	Positiv
	6.6	769	4	e
CFLAR	AC25353	0.424540	3.97E-2	Positiv
	6.6	389	6	e
MAPK8	AC09073	0.653961	3.08E-7	Positiv
	9.1	551	0	e
ATRX	AC09073	0.707784	5.03E-8	Positiv
	9.1	354	7	e
OTULIN	AC09073	0.792983	2.91E-1	Positiv

	9.1	374	23	e
MAP3K7	AC09073	0.650437	2.94E-6	Positiv
	9.1	258	9	e
BCL2L11	AC09073	0.435940	1.31E-2	Positiv
	9.1	455	7	e
CYLD	AC09073	0.663024	8.05E-7	Positiv
	9.1	213	3	e
IPMK	AC09073	0.646968	2.64E-6	Positiv
	9.1	171	8	e
KLF9	AC09073	0.410525	2.22E-2	Positiv
	9.1	763	4	e
BRAF	AC09073	0.829305	2.05E-1	Positiv
	9.1	533	44	e
CFLAR	AC09073	0.640357	1.59E-6	Positiv
	9.1	455	6	e
MAPK8	AP00087	0.629891	8.58E-6	Positiv
	3.2	488	4	e
ATRX	AP00087	0.722430	2.82E-9	Positiv
	3.2	473	2	e
OTULIN	AP00087	0.727507	3.55E-9	Positiv
	3.2	431	4	e
MAP3K7	AP00087	0.599419	2.09E-5	Positiv
	3.2	768	6	e
BCL2L11	AP00087	0.488138	3.64E-3	Positiv
	3.2	686	5	e
TSC1	AP00087	0.513613	2.36E-3	Positiv
	3.2	492	9	e
CYLD	AP00087	0.634460	5.67E-6	Positiv
	3.2	385	5	e
IPMK	AP00087	0.570007	5.43E-5	Positiv
	3.2	015	0	e

BRAF	AP00087	0.817637	4.15E-1	Positiv
	3.2	338	37	e
SIRT1	AP00087	0.415635	5.23E-2	Positiv
	3.2	989	5	e
CFLAR	AP00087	0.724900	3.39E-9	Positiv
	3.2	911	3	e
MAPK8	AP00290	0.661815	1.80E-7	Positiv
	7.1	003	2	e
ATRX	AP00290	0.745855	2.04E-1	Positiv
	7.1	292	01	e
OTULIN	AP00290	0.820228	1.10E-1	Positiv
	7.1	829	38	e
MAP3K7	AP00290	0.648794	8.34E-6	Positiv
	7.1	941	9	e
BCL2L11	AP00290	0.496445	1.71E-3	Positiv
	7.1	709	6	e
CYLD	AP00290	0.685333	1.40E-7	Positiv
	7.1	669	9	e
IPMK	AP00290	0.634359	6.03E-6	Positiv
	7.1	982	5	e
KLF9	AP00290	0.441461	2.38E-2	Positiv
	7.1	584	8	e
BRAF	AP00290	0.824623	2.03E-1	Positiv
	7.1	109	41	e
CFLAR	AP00290	0.667016	5.49E-7	Positiv
	7.1	8	4	e
TRAF2	AC01097	0.427908	1.47E-2	Positiv
	3.2	966	6	e
MAPK8	AC00526	0.672857	1.00E-7	Positiv
	1.1	084	5	e
ATRX	AC00526	0.802899	1.35E-1	Positiv

	1.1	821	28	e
OTULIN	AC00526	0.765795	4.97E-1	Positiv
	1.1	633	10	e
STUB1	AC00526	-0.44323	1.37E-2	Negati
	1.1	4844	8	ve
MAP3K7	AC00526	0.683803	4.26E-7	Positiv
	1.1	926	9	e
BCL2L11	AC00526	0.442101	1.95E-2	Positiv
	1.1	522	8	e
MPG	AC00526	-0.44441	9.45E-2	Negati
	1.1	987	9	ve
TSC1	AC00526	0.409393	3.05E-2	Positiv
	1.1	788	4	e
CYLD	AC00526	0.664005	4.18E-7	Positiv
	1.1	08	3	e
FADD	AC00526	-0.46938	2.67E-3	Negati
	1.1	3297	2	ve
IPMK	AC00526	0.630922	4.67E-6	Positiv
	1.1	772	4	e
KLF9	AC00526	0.445082	7.68E-2	Positiv
	1.1	167	9	e
BRAF	AC00526	0.825172	9.15E-1	Positiv
	1.1	415	42	e
SIRT1	AC00526	0.466870	6.27E-3	Positiv
	1.1	918	2	e
CFLAR	AC00526	0.656320	6.68E-7	Positiv
	1.1	494	1	e
MAPK8	AL59072	0.672188	1.59E-7	Positiv
	3.1	924	5	e
ATRX	AL59072	0.756041	1.03E-1	Positiv
	3.1	906	05	e

OTULIN	AL59072	0.828633	5.58E-1	Positiv
	3.1	135	44	e
MAP3K7	AL59072	0.641831	6.44E-6	Positiv
	3.1	514	7	e
BCL2L11	AL59072	0.505226	6.18E-3	Positiv
	3.1	281	8	e
CYLD	AL59072	0.728721	1.23E-9	Positiv
	3.1	948	4	e
IPMK	AL59072	0.644550	1.20E-6	Positiv
	3.1	155	7	e
KLF9	AL59072	0.473592	6.29E-3	Positiv
	3.1	567	3	e
BRAF	AL59072	0.846670	2.19E-1	Positiv
	3.1	331	56	e
CFLAR	AL59072	0.710654	4.99E-8	Positiv
	3.1	878	8	e
CYLD	AC10469	0.469310	2.74E-3	Positiv
	9.1	996	2	e
CFLAR	AC10469	0.442802	1.57E-2	Positiv
	9.1	41	8	e
OTULIN	AC01865	0.410251	2.40E-2	Positiv
	3.3	715	4	e
TSC1	AC01865	0.500798	3.34E-3	Positiv
	3.3	609	7	e
BRAF	AC01865	0.436484	1.11E-2	Positiv
	3.3	727	7	e
CFLAR	AC01865	0.562124	2.22E-4	Positiv
	3.3	633	8	e
PANX1	LINC016	0.512778	3.28E-3	Positiv
	14	449	9	e
AXL	LINC016	0.600139	1.43E-5	Positiv

	14	453	6	e
KLF9	LINC016	0.429840	8.25E-2	Positiv
	14	892	7	e
MAPK8	AL11738	0.603940	1.88E-5	Positiv
	1.1	691	7	e
ATRX	AL11738	0.682331	1.23E-7	Positiv
	1.1	69	8	e
OTULIN	AL11738	0.738830	1.42E-9	Positiv
	1.1	765	8	e
MAP3K7	AL11738	0.590109	2.64E-5	Positiv
	1.1	018	4	e
BCL2L11	AL11738	0.474974	3.90E-3	Positiv
	1.1	415	3	e
TSC1	AL11738	0.453743	4.83E-3	Positiv
	1.1	584	0	e
CYLD	AL11738	0.622511	6.27E-6	Positiv
	1.1	025	2	e
IPMK	AL11738	0.511945	4.55E-3	Positiv
	1.1	665	9	e
BRAF	AL11738	0.789567	1.71E-1	Positiv
	1.1	96	21	e
CFLAR	AL11738	0.705979	2.12E-8	Positiv
	1.1	151	6	e
MYC	FAM222	0.556774	2.60E-4	Positiv
	A-AS1	841	7	e
TSC1	AC13219	0.543135	1.14E-4	Positiv
	2.2	898	4	e
ID1	SNHG11	0.409739	2.77E-2	Positiv
		065	4	e
MYC	SNHG11	0.407899	4.62E-2	Positiv
		349	4	e

FAS	SNHG11	-0.45759	1.38E-3	Negati
		3408	0	ve
SPATA2	SNHG11	0.657637	2.83E-7	Positiv
		014	1	e
MAPK8	AL44212	0.588977	4.71E-5	Positiv
	5.2	178	4	e
ATRX	AL44212	0.726866	6.20E-9	Positiv
	5.2	51	4	e
OTULIN	AL44212	0.765556	6.38E-1	Positiv
	5.2	475	10	e
MAP3K7	AL44212	0.629389	1.15E-6	Positiv
	5.2	324	3	e
BCL2L11	AL44212	0.470880	1.60E-3	Positiv
	5.2	035	2	e
CYLD	AL44212	0.638820	4.07E-6	Positiv
	5.2	05	6	e
IPMK	AL44212	0.536191	2.26E-4	Positiv
	5.2	85	3	e
KLF9	AL44212	0.432385	3.84E-2	Positiv
	5.2	951	7	e
BRAF	AL44212	0.742281	5.86E-1	Positiv
	5.2	114	00	e
CFLAR	AL44212	0.671416	2.71E-7	Positiv
	5.2	411	5	e
ATRX	AC01592	0.427007	1.92E-2	Positiv
	2.3	374	6	e
MAP3K7	AC01592	0.417405	3.15E-2	Positiv
	2.3	921	5	e
CYLD	AC01592	0.439358	4.57E-2	Positiv
	2.3	975	8	e
KLF9	AC01592	0.495974	2.04E-3	Positiv

	2.3	345	6	e
BRAF	AC01592	0.416532	4.05E-2	Positiv
	2.3	48	5	e
TSC1	AC08774	0.402068	2.30E-2	Positiv
	1.1	894	3	e
MAPK8	MCM3A	0.617142	1.33E-6	Positiv
	P-AS1	53	0	e
ATRX	MCM3A	0.720205	1.86E-9	Positiv
	P-AS1	159	1	e
OTULIN	MCM3A	0.770009	5.83E-1	Positiv
	P-AS1	975	12	e
MAP3K7	MCM3A	0.658090	2.10E-7	Positiv
	P-AS1	716	1	e
BCL2L11	MCM3A	0.474478	4.63E-3	Positiv
	P-AS1	281	3	e
TSC1	MCM3A	0.540500	3.56E-4	Positiv
	P-AS1	412	4	e
CYLD	MCM3A	0.627706	3.09E-6	Positiv
	P-AS1	886	3	e
IPMK	MCM3A	0.609629	8.59E-5	Positiv
	P-AS1	96	9	e
BRAF	MCM3A	0.798937	1.99E-1	Positiv
	P-AS1	809	26	e
SIRT1	MCM3A	0.415136	6.03E-2	Positiv
	P-AS1	97	5	e
CFLAR	MCM3A	0.713482	4.98E-8	Positiv
	P-AS1	822	9	e
MAPK8	N4BP2L	0.601237	7.97E-5	Positiv
	2-IT2	469	7	e
ATRX	N4BP2L	0.774462	4.79E-1	Positiv
	2-IT2	808	14	e

OTULIN	N4BP2L	0.748041	2.54E-1	Positiv
	2-IT2	328	02	e
MAP3K7	N4BP2L	0.671364	2.81E-7	Positiv
	2-IT2	566	5	e
CYLD	N4BP2L	0.626613	5.86E-6	Positiv
	2-IT2	202	3	e
IPMK	N4BP2L	0.591121	1.57E-5	Positiv
	2-IT2	052	4	e
KLF9	N4BP2L	0.413808	8.79E-2	Positiv
	2-IT2	183	5	e
BRAF	N4BP2L	0.740708	2.52E-9	Positiv
	2-IT2	553	9	e
CFLAR	N4BP2L	0.664009	4.17E-7	Positiv
	2-IT2	239	3	e
STUB1	MCF2L-	0.423906	4.78E-2	Positiv
	AS1	587	6	e
MAPK8	LINC005	0.417865	2.76E-2	Positiv
	13	583	5	e
ATRX	LINC005	0.496940	1.42E-3	Positiv
	13	98	6	e
OTULIN	LINC005	0.561297	3.26E-4	Positiv
	13	489	8	e
MAP3K7	LINC005	0.406091	7.62E-2	Positiv
	13	552	4	e
CYLD	LINC005	0.425057	3.41E-2	Positiv
	13	95	6	e
BRAF	LINC005	0.645328	7.36E-6	Positiv
	13	616	8	e
CFLAR	LINC005	0.543723	8.80E-4	Positiv
	13	484	5	e
MAPK8	AC01054	0.578250	1.01E-5	Positiv

	2.5	065	1	e
ATRX	AC01054	0.526857	1.13E-4	Positiv
	2.5	811	1	e
OTULIN	AC01054	0.719785	2.65E-9	Positiv
	2.5	089	1	e
MAP3K7	AC01054	0.546608	2.48E-4	Positiv
	2.5	125	5	e
BCL2L11	AC01054	0.497345	1.22E-3	Positiv
	2.5	186	6	e
TSC1	AC01054	0.459799	6.67E-3	Positiv
	2.5	178	1	e
CYLD	AC01054	0.594795	2.36E-5	Positiv
	2.5	516	5	e
IPMK	AC01054	0.474648	4.36E-3	Positiv
	2.5	995	3	e
BRAF	AC01054	0.651564	1.43E-6	Positiv
	2.5	114	9	e
CFLAR	AC01054	0.682971	7.78E-7	Positiv
	2.5	159	9	e
MAPK8	AC08411	0.566875	2.40E-4	Positiv
	7.1	27	9	e
ATRX	AC08411	0.517697	4.66E-4	Positiv
	7.1	431	0	e
OTULIN	AC08411	0.718368	8.71E-9	Positiv
	7.1	259	1	e
MAP3K7	AC08411	0.607137	3.35E-5	Positiv
	7.1	098	8	e
CYLD	AC08411	0.579624	5.11E-5	Positiv
	7.1	064	2	e
IPMK	AC08411	0.516657	7.06E-4	Positiv
	7.1	511	0	e

KLF9	AC08411	0.406393	7.01E-2	Positiv
	7.1	908	4	e
BRAF	AC08411	0.640455	1.50E-6	Positiv
	7.1	78	6	e
CFLAR	AC08411	0.582215	1.42E-5	Positiv
	7.1	403	2	e
AXL	AC08403	0.452708	6.75E-3	Positiv
	3.3	773	0	e
TSC1	LENG8-	0.564320	7.97E-4	Positiv
	AS1	668	9	e
MAPK8	AC01581	0.548898	9.01E-4	Positiv
	3.1	587	6	e
ATRX	AC01581	0.654082	2.85E-7	Positiv
	3.1	65	0	e
OTULIN	AC01581	0.626814	5.21E-6	Positiv
	3.1	326	3	e
MAP3K7	AC01581	0.492782	6.66E-3	Positiv
	3.1	563	6	e
TSC1	AC01581	0.456271	2.12E-3	Positiv
	3.1	632	0	e
CYLD	AC01581	0.486717	6.09E-3	Positiv
	3.1	088	5	e
IPMK	AC01581	0.491837	9.43E-3	Positiv
	3.1	022	6	e
BRAF	AC01581	0.704845	5.20E-8	Positiv
	3.1	103	6	e
CFLAR	AC01581	0.559114	8.92E-4	Positiv
	3.1	662	8	e
MAPK8	AC11249	0.575977	3.05E-5	Positiv
	6.1	962	1	e
ATRX	AC11249	0.587131	1.20E-5	Positiv

	6.1	187	3	e
OTULIN	AC11249	0.737246	6.06E-9	Positiv
	6.1	251	8	e
MAP3K7	AC11249	0.581336	2.19E-5	Positiv
	6.1	946	2	e
BCL2L11	AC11249	0.475787	2.94E-3	Positiv
	6.1	24	3	e
CYLD	AC11249	0.655639	1.04E-7	Positiv
	6.1	78	0	e
IPMK	AC11249	0.529074	4.51E-4	Positiv
	6.1	594	2	e
KLF9	AC11249	0.480018	6.66E-3	Positiv
	6.1	187	4	e
BRAF	AC11249	0.702923	2.36E-8	Positiv
	6.1	512	5	e
CFLAR	AC11249	0.692374	7.68E-8	Positiv
	6.1	56	2	e
PANX1	MHENC	-0.40131	2.82E-2	Negati
	R	0218	3	ve
SPATA2	MHENC	0.470444	1.86E-3	Positiv
	R	884	2	e
AXL	MIR4435	0.458436	1.04E-3	Positiv
	-2HG	091	0	e
CFLAR	MIR4435	0.523528	4.42E-4	Positiv
	-2HG	926	1	e
ATRX	ZKSCA	0.520304	1.63E-4	Positiv
	N2-DT	489	0	e
OTULIN	ZKSCA	0.530475	2.51E-4	Positiv
	N2-DT	977	2	e
MAP3K7	ZKSCA	0.464984	1.18E-3	Positiv
	N2-DT	544	1	e

TSC1	ZKSCA	0.565439	4.72E-4	Positiv
	N2-DT	666	9	e
BRAF	ZKSCA	0.576167	2.78E-5	Positiv
	N2-DT	475	1	e
CFLAR	ZKSCA	0.541057	2.80E-4	Positiv
	N2-DT	818	4	e
MYC	MAFG-	0.405321	9.42E-2	Positiv
	DT	025	4	e
MAPK8	AC02221	0.589143	4.32E-5	Positiv
	1.1	779	4	e
ATRX	AC02221	0.634075	7.14E-6	Positiv
	1.1	888	5	e
OTULIN	AC02221	0.746366	1.25E-1	Positiv
	1.1	209	01	e
MAP3K7	AC02221	0.528335	6.12E-4	Positiv
	1.1	336	2	e
BCL2L11	AC02221	0.455268	2.95E-3	Positiv
	1.1	484	0	e
CYLD	AC02221	0.583370	7.97E-5	Positiv
	1.1	08	3	e
IPMK	AC02221	0.535665	2.83E-4	Positiv
	1.1	878	3	e
BRAF	AC02221	0.744125	1.04E-1	Positiv
	1.1	212	00	e
CFLAR	AC02221	0.652257	9.20E-7	Positiv
	1.1	883	0	e
TRAF2	AC00906	0.415643	5.22E-2	Positiv
	5.2	367	5	e
MAPK8	AC00906	-0.41630	4.32E-2	Negati
	5.2	8099	5	ve
STUB1	AC00906	0.512930	3.09E-3	Positiv

	5.2	473	9	e
TSC1	TRIM31-	0.473288	6.99E-3	Positiv
	AS1	562	3	e
BRAF	TRIM31-	0.414934	6.39E-2	Positiv
	AS1	737	5	e
CFLAR	TRIM31-	0.430781	6.22E-2	Positiv
	AS1	677	7	e
MAPK8	AC09378	0.639904	2.10E-6	Positiv
	8.1	92	6	e
ATRX	AC09378	0.737227	6.16E-9	Positiv
	8.1	683	8	e
OTULIN	AC09378	0.750493	2.39E-1	Positiv
	8.1	624	03	e
MAP3K7	AC09378	0.656734	5.10E-7	Positiv
	8.1	707	1	e
BCL2L11	AC09378	0.405343	9.37E-2	Positiv
	8.1	293	4	e
CYLD	AC09378	0.627426	3.64E-6	Positiv
	8.1	45	3	e
IPMK	AC09378	0.640301	1.65E-6	Positiv
	8.1	581	6	e
KLF9	AC09378	0.406936	6.03E-2	Positiv
	8.1	774	4	e
BRAF	AC09378	0.774300	5.71E-1	Positiv
	8.1	736	14	e
SIRT1	AC09378	0.403932	1.38E-2	Positiv
	8.1	681	3	e
CFLAR	AC09378	0.656839	4.76E-7	Positiv
	8.1	646	1	e
MAPK8	AC01683	0.665274	1.78E-7	Positiv
	1.4	138	3	e

ATRX	AC01683	0.725531	1.97E-9	Positiv
	1.4	325	3	e
OTULIN	AC01683	0.781156	2.84E-1	Positiv
	1.4	117	17	e
MAP3K7	AC01683	0.598164	4.05E-5	Positiv
	1.4	264	6	e
BCL2L11	AC01683	0.461283	4.08E-3	Positiv
	1.4	989	1	e
CYLD	AC01683	0.686633	5.42E-8	Positiv
	1.4	859	0	e
IPMK	AC01683	0.631223	3.90E-6	Positiv
	1.4	35	4	e
KLF9	AC01683	0.405511	8.94E-2	Positiv
	1.4	467	4	e
BRAF	AC01683	0.846385	3.54E-1	Positiv
	1.4	17	56	e
CFLAR	AC01683	0.680419	4.87E-7	Positiv
	1.4	76	8	e
MAPK8	AC10805	0.609972	7.12E-5	Positiv
	8.1	966	9	e
ATRX	AC10805	0.638563	4.76E-6	Positiv
	8.1	888	6	e
OTULIN	AC10805	0.727460	3.70E-9	Positiv
	8.1	157	4	e
MAP3K7	AC10805	0.545294	4.42E-4	Positiv
	8.1	023	5	e
BCL2L11	AC10805	0.475140	3.68E-3	Positiv
	8.1	791	3	e
TSC1	AC10805	0.427913	1.47E-2	Positiv
	8.1	132	6	e
CYLD	AC10805	0.618692	5.53E-6	Positiv

	8.1	569	1	e
IPMK	AC10805	0.497658	1.09E-3	Positiv
	8.1	307	6	e
BRAF	AC10805	0.785187	2.85E-1	Positiv
	8.1	997	19	e
CFLAR	AC10805	0.730590	2.37E-9	Positiv
	8.1	694	5	e
TSC1	SNHG20	0.493088	5.95E-3	Positiv
		49	6	e
MAPK8	AC24510	0.403251	1.66E-2	Positiv
	0.7	822	3	e
ATRX	AC24510	0.445328	7.10E-2	Positiv
	0.7	394	9	e
CYLD	AC24510	0.413819	8.77E-2	Positiv
	0.7	415	5	e
BRAF	AC24510	0.517117	5.88E-4	Positiv
	0.7	764	0	e
CFLAR	AC24510	0.541277	2.55E-4	Positiv
	0.7	882	4	e
MAPK8	AL13333	0.583128	8.99E-5	Positiv
	0.1	872	3	e
ATRX	AL13333	0.610463	5.44E-5	Positiv
	0.1	609	9	e
OTULIN	AL13333	0.722789	2.07E-9	Positiv
	0.1	824	2	e
MAP3K7	AL13333	0.480211	6.22E-3	Positiv
	0.1	73	4	e
BCL2L11	AL13333	0.475977	2.75E-3	Positiv
	0.1	416	3	e
CYLD	AL13333	0.654428	2.28E-7	Positiv
	0.1	188	0	e

IPMK	AL13333	0.520718	1.38E-4	Positiv
	0.1	125	0	e
KLF9	AL13333	0.443902	1.11E-2	Positiv
	0.1	845	8	e
BRAF	AL13333	0.716750	3.36E-9	Positiv
	0.1	885	0	e
CFLAR	AL13333	0.645775	5.57E-6	Positiv
	0.1	415	8	e
MAPK8	AC01869	0.540486	3.59E-4	Positiv
	5.4	518	4	e
ATRX	AC01869	0.670838	4.03E-7	Positiv
	5.4	054	5	e
OTULIN	AC01869	0.742272	5.91E-1	Positiv
	5.4	217	00	e
MAP3K7	AC01869	0.606371	5.07E-5	Positiv
	5.4	193	8	e
BCL2L11	AC01869	0.481766	3.59E-3	Positiv
	5.4	592	4	e
TSC1	AC01869	0.531811	1.44E-4	Positiv
	5.4	936	2	e
CYLD	AC01869	0.579213	6.26E-5	Positiv
	5.4	912	2	e
IPMK	AC01869	0.499513	5.43E-3	Positiv
	5.4	103	7	e
BRAF	AC01869	0.752085	5.09E-1	Positiv
	5.4	846	04	e
CFLAR	AC01869	0.698261	8.79E-8	Positiv
	5.4	793	4	e
MAPK8	AL15778	0.588382	6.37E-5	Positiv
	6.1	009	4	e
ATRX	AL15778	0.764230	2.53E-1	Positiv

	6.1	249	09	e
OTULIN	AL15778	0.720362	1.63E-9	Positiv
	6.1	406	1	e
MAP3K7	AL15778	0.578570	8.59E-5	Positiv
	6.1	3	2	e
CYLD	AL15778	0.594233	3.16E-5	Positiv
	6.1	309	5	e
IPMK	AL15778	0.584709	4.07E-5	Positiv
	6.1	164	3	e
BRAF	AL15778	0.756107	9.65E-1	Positiv
	6.1	968	06	e
CFLAR	AL15778	0.639596	2.53E-6	Positiv
	6.1	831	6	e
TSC1	AP00162	0.427793	1.52E-2	Positiv
	8.1	081	6	e
MAPK8	AC01053	0.488778	2.89E-3	Positiv
	6.2	168	5	e
ATRX	AC01053	0.538211	9.54E-4	Positiv
	6.2	38	4	e
OTULIN	AC01053	0.599636	1.86E-5	Positiv
	6.2	608	6	e
MAP3K7	AC01053	0.434228	2.20E-2	Positiv
	6.2	259	7	e
BCL2L11	AC01053	0.448605	2.52E-2	Positiv
	6.2	988	9	e
CYLD	AC01053	0.497810	1.03E-3	Positiv
	6.2	529	6	e
IPMK	AC01053	0.403818	1.42E-2	Positiv
	6.2	677	3	e
BRAF	AC01053	0.646111	4.51E-6	Positiv
	6.2	16	8	e

CFLAR	AC01053	0.621290	1.26E-6	Positiv
	6.2	482	1	e
TRAF2	AC08412	0.466925	6.16E-3	Positiv
	5.4	047	2	e
MAPK8	AL02157	0.566407	2.99E-4	Positiv
	8.1	726	9	e
ATRX	AL02157	0.619556	3.39E-6	Positiv
	8.1	59	1	e
OTULIN	AL02157	0.766724	1.88E-1	Positiv
	8.1	169	10	e
MAP3K7	AL02157	0.622640	5.82E-6	Positiv
	8.1	923	2	e
CYLD	AL02157	0.594573	2.65E-5	Positiv
	8.1	353	5	e
IPMK	AL02157	0.496177	1.89E-3	Positiv
	8.1	808	6	e
BRAF	AL02157	0.771912	7.59E-1	Positiv
	8.1	546	13	e
CFLAR	AL02157	0.621424	1.17E-6	Positiv
	8.1	572	1	e
ATRX	AL44522	0.425332	3.14E-2	Positiv
	2.1	436	6	e
OTULIN	AL44522	0.484029	1.60E-3	Positiv
	2.1	478	4	e
TSC1	AL44522	0.445715	6.29E-2	Positiv
	2.1	916	9	e
BRAF	AL44522	0.550513	4.39E-4	Positiv
	2.1	639	6	e
CFLAR	AL44522	0.483121	2.21E-3	Positiv
	2.1	295	4	e
MAPK8	AC10872	0.572729	1.47E-5	Positiv

	7.1	946	0	e
ATRX	AC10872	0.695056	1.02E-8	Positiv
	7.1	182	2	e
OTULIN	AC10872	0.706424	1.49E-8	Positiv
	7.1	21	6	e
MAP3K7	AC10872	0.494762	3.21E-3	Positiv
	7.1	128	6	e
BCL2L11	AC10872	0.441520	2.34E-2	Positiv
	7.1	349	8	e
CYLD	AC10872	0.636029	2.21E-6	Positiv
	7.1	486	5	e
IPMK	AC10872	0.572525	1.62E-5	Positiv
	7.1	656	0	e
KLF9	AC10872	0.400024	4.00E-2	Positiv
	7.1	874	3	e
BRAF	AC10872	0.732766	3.44E-9	Positiv
	7.1	493	6	e
CFLAR	AC10872	0.540094	4.25E-4	Positiv
	7.1	703	4	e
TSC1	AP00662	0.431056	5.73E-2	Positiv
	1.4	752	7	e
MAPK8	AC02406	0.423473	5.43E-2	Positiv
	0.1	742	6	e
ATRX	AC02406	0.511670	5.07E-3	Positiv
	0.1	893	9	e
OTULIN	AC02406	0.555059	5.68E-4	Positiv
	0.1	656	7	e
MAP3K7	AC02406	0.581912	1.65E-5	Positiv
	0.1	006	2	e
TSC1	AC02406	0.441625	2.26E-2	Positiv
	0.1	476	8	e

IPMK	AC02406	0.461457	3.85E-3	Positiv
	0.1	808	1	e
BRAF	AC02406	0.578146	1.06E-5	Positiv
	0.1	135	1	e
CFLAR	AC02406	0.452797	6.56E-3	Positiv
	0.1	987	0	e
MAPK8	AC00811	0.576987	1.87E-5	Positiv
	5.3	328	1	e
ATRX	AC00811	0.719324	3.91E-9	Positiv
	5.3	534	1	e
OTULIN	AC00811	0.722869	1.94E-9	Positiv
	5.3	178	2	e
MAP3K7	AC00811	0.557101	2.24E-4	Positiv
	5.3	798	7	e
BCL2L11	AC00811	0.427648	1.58E-2	Positiv
	5.3	951	6	e
TSC1	AC00811	0.404643	1.14E-2	Positiv
	5.3	224	3	e
CYLD	AC00811	0.598252	3.87E-5	Positiv
	5.3	264	6	e
IPMK	AC00811	0.505529	5.50E-3	Positiv
	5.3	748	8	e
BRAF	AC00811	0.766630	2.08E-1	Positiv
	5.3	496	10	e
CFLAR	AC00811	0.640672	1.31E-6	Positiv
	5.3	111	6	e
MYC	AC00632	0.406642	6.54E-2	Positiv
	9.1	016	4	e
MAPK8	Z83843.1	0.595640	1.52E-5	Positiv
		824	5	e
ATRX	Z83843.1	0.820066	1.38E-1	Positiv

		456	38	e
OTULIN	Z83843.1	0.677656	3.47E-7	Positiv
		11	7	e
MAP3K7	Z83843.1	0.592747	6.81E-5	Positiv
		986	5	e
CYLD	Z83843.1	0.604360	1.50E-5	Positiv
		232	7	e
IPMK	Z83843.1	0.616290	2.14E-6	Positiv
		592	0	e
BRAF	Z83843.1	0.767236	1.10E-1	Positiv
		357	10	e
CFLAR	Z83843.1	0.583527	7.37E-5	Positiv
		066	3	e
SPATA2	AC07411	0.409272	3.15E-2	Positiv
	7.1	032	4	e
TSC1	AC07411	0.433992	2.36E-2	Positiv
	7.1	797	7	e
MAPK8	AC07877	0.606087	5.91E-5	Positiv
	8.1	394	8	e
ATRX	AC07877	0.636988	1.24E-6	Positiv
	8.1	706	5	e
OTULIN	AC07877	0.716946	2.85E-9	Positiv
	8.1	348	0	e
STUB1	AC07877	-0.40340	1.59E-2	Negati
	8.1	7269	3	ve
MAP3K7	AC07877	0.621302	1.25E-6	Positiv
	8.1	72	1	e
BCL2L11	AC07877	0.428111	1.38E-2	Positiv
	8.1	222	6	e
TSC1	AC07877	0.411650	1.62E-2	Positiv
	8.1	049	4	e

CYLD	AC07877	0.562602	1.78E-4	Positiv
	8.1	259	8	e
FADD	AC07877	-0.43548	1.50E-2	Negati
	8.1	1066	7	ve
IPMK	AC07877	0.561627	2.79E-4	Positiv
	8.1	575	8	e
BRAF	AC07877	0.739370	8.67E-9	Positiv
	8.1	875	9	e
CFLAR	AC07877	0.615473	3.38E-6	Positiv
	8.1	296	0	e
ATRX	TSPOAP	0.584778	3.93E-5	Positiv
	1-AS1	658	3	e
OTULIN	TSPOAP	0.561867	2.50E-4	Positiv
	1-AS1	04	8	e
MAP3K7	TSPOAP	0.428721	1.15E-2	Positiv
	1-AS1	076	6	e
TSC1	TSPOAP	0.446406	5.06E-2	Positiv
	1-AS1	498	9	e
BRAF	TSPOAP	0.577889	1.20E-5	Positiv
	1-AS1	647	1	e
CFLAR	TSPOAP	0.489070	2.59E-3	Positiv
	1-AS1	923	5	e
TSC1	AL13341	0.595560	1.58E-5	Positiv
	0.1	854	5	e
CFLAR	AL13341	0.407004	5.92E-2	Positiv
	0.1	175	4	e
MAPK8	AF11782	0.643123	2.90E-6	Positiv
	9.1	2	7	e
ATRX	AF11782	0.743752	1.48E-1	Positiv
	9.1	877	00	e
OTULIN	AF11782	0.788348	7.19E-1	Positiv

	9.1	49	21	e
MAP3K7	AF11782	0.670027	7.04E-7	Positiv
	9.1	699	5	e
BCL2L11	AF11782	0.459104	8.39E-3	Positiv
	9.1	173	1	e
CYLD	AF11782	0.668833	1.59E-7	Positiv
	9.1	027	4	e
IPMK	AF11782	0.618496	6.18E-6	Positiv
	9.1	47	1	e
KLF9	AF11782	0.428867	1.10E-2	Positiv
	9.1	531	6	e
BRAF	AF11782	0.807443	3.85E-1	Positiv
	9.1	822	31	e
SIRT1	AF11782	0.417501	3.07E-2	Positiv
	9.1	613	5	e
CFLAR	AF11782	0.662611	1.06E-7	Positiv
	9.1	012	2	e
MAPK8	AL03167	0.427328	1.74E-2	Positiv
	3.1	547	6	e
ATRX	AL03167	0.628199	2.32E-6	Positiv
	3.1	811	3	e
OTULIN	AL03167	0.522590	6.47E-4	Positiv
	3.1	854	1	e
MAP3K7	AL03167	0.525289	2.15E-4	Positiv
	3.1	054	1	e
CYLD	AL03167	0.425396	3.09E-2	Positiv
	3.1	861	6	e
IPMK	AL03167	0.417929	2.71E-2	Positiv
	3.1	97	5	e
BRAF	AL03167	0.595146	1.96E-5	Positiv
	3.1	187	5	e

CFLAR	AL03167	0.492376	7.74E-3	Positiv
	3.1	032	6	e
MAPK8	FMR1-IT	0.566914	2.36E-4	Positiv
	1	569	9	e
ATRX	FMR1-IT	0.738993	1.23E-9	Positiv
	1	383	8	e
OTULIN	FMR1-IT	0.644796	1.03E-6	Positiv
	1	912	7	e
MAP3K7	FMR1-IT	0.547548	1.64E-4	Positiv
	1	17	5	e
CYLD	FMR1-IT	0.604057	1.77E-5	Positiv
	1	251	7	e
IPMK	FMR1-IT	0.591214	1.50E-5	Positiv
	1	003	4	e
BRAF	FMR1-IT	0.755513	1.74E-1	Positiv
	1	268	05	e
CFLAR	FMR1-IT	0.579488	5.47E-5	Positiv
	1	874	2	e
MAPK8	AC00793	0.596996	7.48E-5	Positiv
	8.3	304	6	e
ATRX	AC00793	0.753810	9.38E-1	Positiv
	8.3	216	05	e
OTULIN	AC00793	0.712548	1.07E-8	Positiv
	8.3	701	8	e
MAP3K7	AC00793	0.556906	2.45E-4	Positiv
	8.3	503	7	e
BCL2L11	AC00793	0.427510	1.65E-2	Positiv
	8.3	728	6	e
TSC1	AC00793	0.403307	1.64E-2	Positiv
	8.3	344	3	e
CYLD	AC00793	0.600608	1.11E-5	Positiv

	8.3	447	6	e
IPMK	AC00793	0.546402	2.72E-4	Positiv
	8.3	777	5	e
BRAF	AC00793	0.809543	2.43E-1	Positiv
	8.3	844	32	e
CFLAR	AC00793	0.622987	4.77E-6	Positiv
	8.3	476	2	e
MAPK8	AC08758	0.522452	6.85E-4	Positiv
	8.2	733	1	e
ATRX	AC08758	0.507709	2.37E-3	Positiv
	8.2	33	8	e
OTULIN	AC08758	0.610179	6.36E-5	Positiv
	8.2	152	9	e
MAP3K7	AC08758	0.488720	2.95E-3	Positiv
	8.2	501	5	e
CYLD	AC08758	0.473819	5.82E-3	Positiv
	8.2	543	3	e
FADD	AC08758	-0.41390	8.55E-2	Negati
	8.2	8587	5	ve
IPMK	AC08758	0.520621	1.44E-4	Positiv
	8.2	91	0	e
BRAF	AC08758	0.598443	3.50E-5	Positiv
	8.2	781	6	e
CFLAR	AC08758	0.528962	4.72E-4	Positiv
	8.2	01	2	e
MAPK8	AL13778	0.519426	2.33E-4	Positiv
	2.1	901	0	e
ATRX	AL13778	0.568106	1.34E-4	Positiv
	2.1	785	9	e
OTULIN	AL13778	0.673075	8.59E-7	Positiv
	2.1	798	6	e

MAP3K7	AL13778	0.530361	2.64E-4	Positiv
	2.1	868	2	e
BCL2L11	AL13778	0.437289	8.64E-2	Positiv
	2.1	01	8	e
CYLD	AL13778	0.577211	1.67E-5	Positiv
	2.1	916	1	e
IPMK	AL13778	0.414832	6.57E-2	Positiv
	2.1	236	5	e
BRAF	AL13778	0.687032	4.04E-8	Positiv
	2.1	966	0	e
CFLAR	AL13778	0.699824	2.63E-8	Positiv
	2.1	602	4	e

LncRNAs: Long noncoding RNAs.

Supplementary Table 2 All of the necroptosis-related genes in the article

Genes	Source
FAS	Necroptosis geneset M24779.gmt
FADD	Necroptosis geneset M24779.gmt
FADD	Necroptosis geneset M24779.gmt
MLKL	Necroptosis geneset M24779.gmt
RIPK1	Necroptosis geneset M24779.gmt
RIPK3	Necroptosis geneset M24779.gmt
TLR3	Necroptosis geneset M24779.gmt
TNF	Necroptosis geneset M24779.gmt
	Nicolai S, Pieraccioli M, Peschiaroli A, Melino G, Raschellà G. Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis. Cell Death Dis. 2015 Dec 3;6(12): e2010. doi: 10.1038/cddis.2015.354. PMID: 26633716;
ALK	PMCID: PMC4720889.
APP	Wang L, Shen Q, Liao H, Fu H, Wang Q, Yu J,

Zhang W, Chen C, Dong Y, Yang X, Guo Q, Zhang J, Zhang J, Zhang W, Lin H, Duan Y. Multi-Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation. *Adv Sci (Weinh)*. 2021 Jun;8(11):e2003558. doi: 10.1002/advs.202003558. Epub 2021 Mar 18. PMID: 34105277; PMCID: PMC8188212.

Nicolai S, Pieraccioli M, Peschiaroli A, Melino G, Raschellà G. Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis. *Cell Death Dis*. 2015 Dec 3;6(12):e2010. doi: 10.1038/cddis.2015.354. PMID: 26633716; PMCID: PMC4720889.

ATRX

Najafov A, Zervantonakis IK, Mookhtiar AK, Greninger P, March RJ, Egan RK, Luu HS, Stover DG, Matulonis UA, Benes CH, Yuan J. BRAF and AXL oncogenes drive RIPK3 expression loss in cancer. *PLoS Biol*. 2018 Aug 29;16(8):e2005756. doi: 10.1371/journal.pbio.2005756. PMID: 30157175; PMCID: PMC6114281.

AXL

Petanidis S, Domvri K, Porpodis K, Anestakis D, Freitag L, Hohenforst-Schmidt W, Tsavlis D, Zarogoulidis K. Inhibition of kras-derived exosomes downregulates immunosuppressive BACH2/GATA-3 expression via RIP-3 dependent necroptosis and miR-146/miR-210 modulation. *Biomed Pharmacother*. 2020 Feb;122:109461. doi: 10.1016/j.biopha.2019.109461. Epub 2019 Dec 30. PMID: 31918262.

BACH2

BCL2 Lee KM, Lee H, Han D, Moon WK, Kim K, Oh HJ,

- Choi J, Hwang EH, Kang SE, Im SA, Lee KH, Ryu HS. Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer. *Breast Cancer Res.* 2020 Nov 25;22(1):130. doi: 10.1186/s13058-020-01367-7. PMID: 33239070; PMCID: PMC7687715.
- Locatelli SL, Cleris L, Stirparo GG, Tartari S, Saba E, Pierdominici M, Malorni W, Carbone A, Anichini A, Carlo-Stella C. BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. *Leukemia.* 2014 Sep;28(9):1861-71. doi: 10.1038/leu.2014.81. Epub 2014 Feb 24. PMID: 24561519.
- Kim JY, Kim YJ, Lee S, Park JH. BNIP3 is a mediator of TNF-induced necrotic cell death. *Apoptosis.* 2011 Feb;16(2):114-26. doi: 10.1007/s10495-010-0550-4. PMID: 20963496.
- Najafov A, Zervantonakis IK, Mookhtiar AK, Greninger P, March RJ, Egan RK, Luu HS, Stover DG, Matulonis UA, Benes CH, Yuan J. BRAF and AXL oncogenes drive RIPK3 expression loss in cancer. *PLoS Biol.* 2018 Aug 29;16(8):e2005756. doi: 10.1371/journal.pbio.2005756. PMID: 30157175; PMCID: PMC6114281.
- Fritsch M, Günther SD, Schwarzer R, Albert MC, Schorn F, Werthenbach JP, Schiffmann LM, Stair N, Stocks H, Seeger JM, Lamkanfi M, Krönke M, Pasparakis M, Kashkar H. Caspase-8 is the

molecular switch for apoptosis, necroptosis and pyroptosis. *Nature*. 2019 Nov;575(7784):683-687. doi: 10.1038/s41586-019-1770-6. Epub 2019 Nov 20. PMID: 31748744.

Qiu X, Klausen C, Cheng JC, Leung PC. CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells. *Cell Death Dis*. 2015 Aug 27;6(8):e1864. doi: 10.1038/cddis.2015.229.

CD40 PMID: 26313915; PMCID: PMC4558516.

Medrano RFV, Hunger A, Catani JPP, Strauss BE. Uncovering the immunotherapeutic cycle initiated by p19Arf and interferon- β gene transfer to cancer cells: An inducer of immunogenic cell death. *Oncoimmunology*. 2017 May 19;6(7):e1329072. doi:

CDKN 10.1080/2162402X.2017.1329072. PMID: 28811972;
2A PMCID: PMC5543818.

Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, Melisi D, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Biccato S, Blazar BR, Sahin U, Murray PJ, Bronte V. Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. *Nat Commun*. 2018 Dec 5;9(1):5193. doi: 10.1038/s41467-018-07654-4. PMID:

CFLAR 30518925; PMCID: PMC6281604.

Lork M, Verhelst K, Beyaert R. CYLD, A20 and OTULIN deubiquitinases in NF- κ B signaling and cell death: so similar, yet so different. *Cell Death*

CYLD Differ. 2017 Jul;24(7):1172-1183. doi:

10.1038/cdd.2017.46. Epub 2017 Mar 31. PMID: 28362430; PMCID: PMC5520167.

Dunker W, Ye X, Zhao Y, Liu L, Richardson A, Karijolich J. TDP-43 prevents endogenous RNAs from triggering a lethal RIG-I-dependent interferon response. *Cell Rep.* 2021 Apr 13;35(2):108976. doi: 10.1016/j.celrep.2021.108976. PMID: 33852834; DDX58 PMCID: PMC8109599.

McComb S, Aguadé-Gorgorió J, Harder L, Marovca B, Cario G, Eckert C, Schrappe M, Stanulla M, von Stackelberg A, Bourquin JP, Bornhauser BC. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. *Sci Transl Med.* 2016 May 18;8(339):339ra70. doi: 10.1126/scitranslmed.aad2986. PMID: 27194728. DIABL O

Smith AD, Lu C, Payne D, Paschall AV, Klement JD, Redd PS, Ibrahim ML, Yang D, Han Q, Liu Z, Shi H, Hartney TJ, Nayak-Kapoor A, Liu K. Autocrine IL6-Mediated Activation of the STAT3-DNMT Axis Silences the TNF α -RIP1 Necroptosis Pathway to Sustain Survival and Accumulation of Myeloid-Derived Suppressor Cells. *Cancer Res.* 2020 Aug 1;80(15):3145-3156. doi: 10.1158/0008-5472.CAN-19-3670. Epub 2020 Jun 17. PMID: 32554751; PMCID: PMC7416440. DNMT 1

Zhao Q, Kretschmer N, Bauer R, Efferth T. Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib. *Int J Cancer.* 2015 Sep 15;137(6):1446-56. doi: EGFR

10.1002/ijc.29483. Epub 2015 Mar 6. PMID: 25688715.

Hillert LK, Bettermann-Bethge K, Nimmagadda SC, Fischer T, Naumann M, Lavrik IN. Targeting RIPK1 in AML cells carrying FLT3-ITD. *Int J Cancer*. 2019 Sep 15;145(6):1558-1569. doi: 10.1002/ijc.32246.

FLT3 Epub 2019 Mar 23. PMID: 30828789.

Petanidis S, Domvri K, Porpodis K, Anestakis D, Freitag L, Hohenforst-Schmidt W, Tsavlis D, Zarogoulidis K. Inhibition of kras-derived exosomes downregulates immunosuppressive BACH2/GATA-3 expression via RIP-3 dependent necroptosis and miR-146/miR-210 modulation. *Biomed Pharmacother*. 2020 Feb;122:109461. doi: 10.1016/j.biopha.2019.109461. Epub 2019 Dec 30.

GATA3 PMID: 31918262.

Carafa V, Nebbioso A, Cuomo F, Rotili D, Cobellis G, Bontempo P, Baldi A, Spugnini EP, Citro G, Chambery A, Russo R, Ruvo M, Ciana P, Maravigna L, Shaik J, Radaelli E, De Antonellis P, Tarantino D, Pirolli A, Ragno R, Zollo M, Stunnenberg HG, Mai A, Altucci L. RIP1-HAT1-SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer. *Clin Cancer Res*. 2018 Jun 15;24(12):2886-2900. doi: 10.1158/1078-0432.CCR-17-3081. Epub 2018 Mar 13.

HAT1 PMID: 29535128.

Tung B, Ma D, Wang S, Oyinlade O, Laterra J, Ying M, Lv SQ, Wei S, Xia S. Krüppel-like factor 9 and

HDAC histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.

BMC Cancer. 2018 Oct 22;18(1):1025. doi: 10.1186/s12885-018-4874-8. PMID: 30348136; PMCID: PMC6198521.

Yan C, Oh JS, Yoo SH, Lee JS, Yoon YG, Oh YJ, Jang MS, Lee SY, Yang J, Lee SH, Kim HY, Yoo YH. The targeted inhibition of mitochondrial Hsp90 overcomes the apoptosis resistance conferred by Bcl-2 in Hep3B cells via necroptosis. *Toxicol Appl Pharmacol.* 2013 Jan 1;266(1):9-18. doi: 10.1016/j.taap.2012.11.001. Epub 2012 Nov 9. PMID: 23147571.

Johnston AN, Ma Y, Liu H, Liu S, Hanna-Addams S, Chen S, Chen C, Wang Z. Necroptosis-blocking compound NBC1 targets heat shock protein 70 to inhibit MLKL polymerization and necroptosis. *Proc Natl Acad Sci U S A.* 2020 Mar 24;117(12):6521-6530. doi: 10.1073/pnas.1916503117. Epub 2020 Mar 10. PMID: 32156734; PMCID: PMC7104336.

Tan HY, Wang N, Chan YT, Zhang C, Guo W, Chen F, Zhong Z, Li S, Feng Y. ID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis. *Cancer Lett.* 2020 Apr 10;475:109-118. doi: 10.1016/j.canlet.2020.01.025. Epub 2020 Jan 28. PMID: 32004572.

Yang Z, Jiang B, Wang Y, Ni H, Zhang J, Xia J, Shi M, Hung LM, Ruan J, Mak TW, Li Q, Han J. 2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter. *Cell Rep.* 2017 May 30;19(9):1846-1857. doi: 10.1016/j.celrep.2017.05.012. PMID: 28564603.

IDH1

- Yang Z, Jiang B, Wang Y, Ni H, Zhang J, Xia J, Shi M, Hung LM, Ruan J, Mak TW, Li Q, Han J. 2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter. *Cell Rep.* 2017 May 30;19(9):1846-1857. doi: 10.1016/j.celrep.2017.05.012. PMID: 28564603.
- IDH2 Dovey CM, Diep J, Clarke BP, Hale AT, McNamara DE, Guo H, Brown NW Jr, Cao JY, Grace CR, Gough PJ, Bertin J, Dixon SJ, Fiedler D, Mocarski ES, Kaiser WJ, Moldoveanu T, York JD, Carette JE. MLKL Requires the Inositol Phosphate Code to Execute Necroptosis. *Mol Cell.* 2018 Jun 7;70(5):936-948.e7. doi: 10.1016/j.molcel.2018.05.010. Epub 2018 Jun 7. PMID: 29883610; PMCID: PMC5994928.
- IPMK Dovey CM, Diep J, Clarke BP, Hale AT, McNamara DE, Guo H, Brown NW Jr, Cao JY, Grace CR, Gough PJ, Bertin J, Dixon SJ, Fiedler D, Mocarski ES, Kaiser WJ, Moldoveanu T, York JD, Carette JE. MLKL Requires the Inositol Phosphate Code to Execute Necroptosis. *Mol Cell.* 2018 Jun 7;70(5):936-948.e7. doi: 10.1016/j.molcel.2018.05.010. Epub 2018 Jun 7. PMID: 29883610; PMCID: PMC5994928.
- ITPK1 Tung B, Ma D, Wang S, Oyinlade O, Lattera J, Ying M, Lv SQ, Wei S, Xia S. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells. *BMC Cancer.* 2018 Oct 22;18(1):1025. doi: 10.1186/s12885-018-4874-8. PMID: 30348136; PMCID: PMC6198521.
- KLF9

- Liu P, Xu B, Shen W, Zhu H, Wu W, Fu Y, Chen H, Dong H, Zhu Y, Miao K, Xu W, Li J. Dysregulation of TNF α -induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. *Leukemia*. 2012 Jun;26(6):1293-300. doi: 10.1038/leu.2011.357. Epub 2011 Dec 13. PMID: 22157808.
- LEF1
- Goodall ML, Fitzwalter BE, Zahedi S, Wu M, Rodriguez D, Mulcahy-Levy JM, Green DR, Morgan M, Cramer SD, Thorburn A. The Autophagy Machinery Controls Cell Death Switching between Apoptosis and Necroptosis. *Dev Cell*. 2016 May 23;37(4):337-349. doi: 10.1016/j.devcel.2016.04.018. PMID: 27219062; PMCID: PMC4886731.
- MAP3
- K7
- Wang Y, Zhao M, He S, Luo Y, Zhao Y, Cheng J, Gong Y, Xie J, Wang Y, Hu B, Tian L, Liu X, Li C, Huang Q. Necroptosis regulates tumor repopulation after radiotherapy via RIP1/RIP3/MLKL/JNK/IL8 pathway. *J Exp Clin Cancer Res*. 2019 Nov 9;38(1):461. doi: 10.1186/s13046-019-1423-5. PMID: 31706322; PMCID: PMC6842489.
- MAPK
- 8
- Allocca M, Corrigan JJ, Mazumder A, Fake KR, Samson LD. Inflammation, necrosis, and the kinase RIP3 are key mediators of AAG-dependent alkylation-induced retinal degeneration. *Sci Signal*. 2019 Feb 12;12(568):eaau9216. doi: 10.1126/scisignal.aau9216. PMID: 30755477; PMCID: PMC7150588.
- MPG
- MYC
- Seong D, Jeong M, Seo J, Lee JY, Hwang CH, Shin

- HC, Shin JY, Nam YW, Jo JY, Lee H, Kim HJ, Kim HR, Oh JH, Ha SJ, Kim SJ, Roe JS, Kim W, Cheong JW, Bae KH, Lee SC, Oberst A, Vandenabeele P, Shin DH, Lee EW, Song J. Identification of MYC as an antinecrotic protein that stifles RIPK1-RIPK3 complex formation. *Proc Natl Acad Sci U S A*. 2020 Aug 18;117(33):19982-19993. doi: 10.1073/pnas.2000979117. Epub 2020 Aug 4. PMID: 32753382; PMCID: PMC7443878.
- Nicolai S, Pieraccioli M, Peschiaroli A, Melino G, Raschella G. Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis. *Cell Death Dis*. 2015 Dec 3;6(12):e2010. doi: 10.1038/cddis.2015.354. PMID: 26633716; PMCID: PMC4720889.
- MYCN Heger K, Wickliffe KE, Ndoja A, Zhang J, Murthy A, Dugger DL, Maltzman A, de Sousa E Melo F, Hung J, Zeng Y, Verschueren E, Kirkpatrick DS, Vucic D, Lee WP, Roose-Girma M, Newman RJ, Warming S, Hsiao YC, Kórmúves LG, Webster JD, Newton K, Dixit VM. OTULIN limits cell death and inflammation by deubiquitinating LUBAC. *Nature*. 2018 Jul;559(7712):120-124. doi: 10.1038/s41586-018-0256-2. Epub 2018 Jun 27. PMID: 29950720.
- OTULIN Douanne T, André-Grégoire G, Trillet K, Thys A, Papin A, Feyeux M, Hulin P, Chiron D, Gavard J, Bidère N. Pannexin-1 limits the production of proinflammatory cytokines during necroptosis. *EMBO Rep*. 2019 Oct 4;20(10):e47840. doi: 10.15252/embr.201947840. Epub 2019 Aug 14.
- PANX1

PMID: 31410978; PMCID: PMC6776911.

Deeraksa A, Pan J, Sha Y, Liu XD, Eissa NT, Lin SH, Yu-Lee LY. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis. *Oncogene*. 2013 Jun 13;32(24):2973-83. doi: 10.1038/onc.2012.309. Epub 2012 Aug 13. PMID: 22890325; PMCID:

PLK1 PMCID: PMC3499666.

Kupka S, De Miguel D, Draber P, Martino L, Surinova S, Rittinger K, Walczak H. SPATA2-Mediated Binding of CYLD to HOIP Enables CYLD Recruitment to Signaling Complexes. *Cell Rep*. 2016 Aug 30;16(9):2271-80. doi: 10.1016/j.celrep.2016.07.086. Epub 2016 Aug

RNF31 18. PMID: 27545878; PMCID: PMC5009064.

Carafa V, Nebbioso A, Cuomo F, Rotili D, Cobellis G, Bontempo P, Baldi A, Spugnini EP, Citro G, Chambery A, Russo R, Ruvo M, Ciana P, Maravigna L, Shaik J, Radaelli E, De Antonellis P, Tarantino D, Pirolli A, Ragno R, Zollo M, Stunnenberg HG, Mai A, Altucci L. RIP1-HAT1-SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer. *Clin Cancer Res*. 2018 Jun 15;24(12):2886-2900. doi: 10.1158/1078-0432.CCR-17-3081. Epub 2018 Mar 13.

SIRT1 PMID: 29535128.

Carafa V, Nebbioso A, Cuomo F, Rotili D, Cobellis G, Bontempo P, Baldi A, Spugnini EP, Citro G, Chambery A, Russo R, Ruvo M, Ciana P, Maravigna L, Shaik J, Radaelli E, De Antonellis P,

SIRT2 Tarantino D, Pirolli A, Ragno R, Zollo M,

- Stunnenberg HG, Mai A, Altucci L. RIP1-HAT1-SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer. *Clin Cancer Res.* 2018 Jun 15;24(12):2886-2900. doi: 10.1158/1078-0432.CCR-17-3081. Epub 2018 Mar 13. PMID: 29535128.
- Tang X, Li Y, Liu L, Guo R, Zhang P, Zhang Y, Zhang Y, Zhao J, Su J, Sun L, Liu Y. Sirtuin 3 induces apoptosis and necroptosis by regulating mutant p53 expression in small-cell lung cancer. *Oncol Rep.* 2020 Feb;43(2):591-600. doi: 10.3892/or.2019.7439. Epub 2019 Dec 17. PMID: 31894331.
- SIRT3 Fauster A, Rebsamen M, Willmann KL, César-Razquin A, Girardi E, Bigenzahn JW, Schischlik F, Scorzoni S, Bruckner M, Konecka J, Hörmann K, Heinz LX, Boztug K, Superti-Furga G. Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking. *Cell Death Differ.* 2019 Jun;26(6):1138-1155. doi: 10.1038/s41418-018-0192-6. Epub 2018 Sep 20. PMID: 30237509; PMCID: PMC6748104.
- SLC39 A7 Kupka S, De Miguel D, Draber P, Martino L, Surinova S, Rittinger K, Walczak H. SPATA2-Mediated Binding of CYLD to HOIP Enables CYLD Recruitment to Signaling Complexes. *Cell Rep.* 2016 Aug 30;16(9):2271-80. doi: 10.1016/j.celrep.2016.07.086. Epub 2016 Aug 18. PMID: 27545878; PMCID: PMC5009064.
- SPATA 2
- SQSTM Goodall ML, Fitzwalter BE, Zahedi S, Wu M,

- 1 Rodriguez D, Mulcahy-Levy JM, Green DR, Morgan M, Cramer SD, Thorburn A. The Autophagy Machinery Controls Cell Death Switching between Apoptosis and Necroptosis. *Dev Cell*. 2016 May 23;37(4):337-349. doi: 10.1016/j.devcel.2016.04.018. PMID: 27219062; PMCID: PMC4886731.
- Wang X, Shao X, Gu L, Jiang K, Wang S, Chen J, Fang J, Guo X, Yuan M, Shi J, Ding C, Meng S, Xu Q. Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells. *J Cell Mol Med*. 2020 Apr;24(7):4286-4297. doi: 10.1111/jcmm.15089. Epub 2020 Feb 26. PMID: STAT3 32100392; PMCID: PMC7171322.
- Tang MB, Li YS, Li SH, Cheng Y, Zhang S, Luo HY, Mao CY, Hu ZW, Schisler JC, Shi CH, Xu YM. Anisomycin prevents OGD-induced necroptosis by regulating the E3 ligase CHIP. *Sci Rep*. 2018 Apr 23;8(1):6379. doi: 10.1038/s41598-018-24414-y. STUB1 PMID: 29686306; PMCID: PMC5913227.
- Dunker W, Ye X, Zhao Y, Liu L, Richardson A, Karijolich J. TDP-43 prevents endogenous RNAs from triggering a lethal RIG-I-dependent interferon response. *Cell Rep*. 2021 Apr 13;35(2):108976. doi: TARDB 10.1016/j.celrep.2021.108976. PMID: 33852834; P PMCID: PMC8109599.
- Nicolai S, Pieraccioli M, Peschiaroli A, Melino G, Raschellà G. Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis. *Cell Death Dis*. 2015 Dec 3;6(12):e2010. TERT doi: 10.1038/cddis.2015.354. PMID: 26633716;

PMCID: PMC4720889.

Seifert L, Werba G, Tiwari S, Giao Ly NN, Alothman S, Alqunaibit D, Avanzi A, Barilla R, Daley D, Greco SH, Torres-Hernandez A, Pergamo M, Ochi A, Zambirinis CP, Pansari M, Rendon M, Tippens D, Hundeyin M, Mani VR, Hajdu C, Engle D, Miller G. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. *Nature*. 2016 Apr 14;532(7598):245-9. doi: 10.1038/nature17403. Epub 2016 Apr 6. Erratum in: *Nature*. 2021 Mar;591(7851):E28. PMID: 27049944; PMCID: PMC4833566.

Borghi A, Verstrepen L, Beyaert R. TRAF2 multitasking in TNF receptor-induced signaling to NF- κ B, MAP kinases and cell death. *Biochem Pharmacol*. 2016 Sep 15;116:1-10. doi: 10.1016/j.bcp.2016.03.009. Epub 2016 Mar 16. PMID: 26993379.

Wang L, Shen Q, Liao H, Fu H, Wang Q, Yu J, Zhang W, Chen C, Dong Y, Yang X, Guo Q, Zhang J, Zhang J, Zhang W, Lin H, Duan Y. Multi-Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation. *Adv Sci (Weinh)*. 2021 Jun;8(11):e2003558. doi: 10.1002/advs.202003558. Epub 2021 Mar 18. PMID: 34105277; PMCID: PMC8188212.

Seifert L, Werba G, Tiwari S, Giao Ly NN, Alothman S, Alqunaibit D, Avanzi A, Barilla R, Daley D, Greco SH, Torres-Hernandez A, Pergamo

M, Ochi A, Zambirinis CP, Pansari M, Rendon M, Tippens D, Hundeyin M, Mani VR, Hajdu C, Engle D, Miller G. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. *Nature*. 2016 Apr 14;532(7598):245-9. doi: 10.1038/nature17403. Epub 2016 Apr 6. Erratum in: *Nature*. 2021 Mar;591(7851):E28. PMID: 27049944; PMCID: PMC4833566.

Borghi A, Verstrepen L, Beyaert R. TRAF2 multitasking in TNF receptor-induced signaling to NF- κ B, MAP kinases and cell death. *Biochem Pharmacol*. 2016 Sep 15;116:1-10. doi: 10.1016/j.bcp.2016.03.009. Epub 2016 Mar 16. PMID: 26993379.

TRAF2

Xie Y, Zhao Y, Shi L, Li W, Chen K, Li M, Chen X, Zhang H, Li T, Matsuzawa-Ishimoto Y, Yao X, Shao D, Ke Z, Li J, Chen Y, Zhang X, Cui J, Cui S, Leng Q, Cadwell K, Li X, Wei H, Zhang H, Li H, Xiao H. Gut epithelial TSC1/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer. *J Clin Invest*. 2020 Apr 1;130(4):2111-2128. doi: 10.1172/JCI133264. PMID: 31961824; PMCID: PMC7108921.

TSC1

Xie Y, Zhao Y, Shi L, Li W, Chen K, Li M, Chen X, Zhang H, Li T, Matsuzawa-Ishimoto Y, Yao X, Shao D, Ke Z, Li J, Chen Y, Zhang X, Cui J, Cui S, Leng Q, Cadwell K, Li X, Wei H, Zhang H, Li H, Xiao H. Gut epithelial TSC1/mTOR controls RIPK3-dependent

TRIM1

necroptosis in intestinal inflammation and cancer. *J Clin Invest*. 2020 Apr 1;130(4):2111-2128. doi:

1

10.1172/JCI133264. PMID: 31961824; PMCID: PMC7108921.

Roedig J, Kowald L, Juretschke T, Karlowitz R, Ahangarian Abhari B, Roedig H, Fulda S, Beli P, van Wijk SJ. USP22 controls necroptosis by regulating receptor-interacting protein kinase 3 ubiquitination. *EMBO Rep.* 2021 Feb 3;22(2):e50163. doi: 10.15252/embr.202050163. Epub 2020 Dec 28.

USP22 PMID: 33369872; PMCID: PMC7857539.

Yang D, Liang Y, Zhao S, Ding Y, Zhuang Q, Shi Q, Ai T, Wu SQ, Han J. ZBP1 mediates interferon-induced necroptosis. *Cell Mol Immunol.* 2020 Apr;17(4):356-368. doi: 10.1038/s41423-019-0237-x. Epub 2019 May 10.

ZBP1 PMID: 31076724; PMCID: PMC7109092.

Supplementary Table 3 The Primer sequences for all long noncoding RNAs and the internal reference gene GAPDH

Gene	Primers: 5'- 3'
AP001469.3	F: CCCATCGCCTTCTGTAATGGA R: TGCTTCGTTTTGACTTCCGC
AC007128.1	F: AGATCCACAATGCCGTAGAC R: CTGGAGGCAGCTGTGTTTAG
LINC02381	F: AAAAGTTGACGCCGCATTCT R: GAGAATGGATTGTGGGTGCC
AC099850.3	F: CGTCTTTCACCCAGCCTCTT R: AAAGCAGGAACCCCTCTGTG
AC010973.2	F: CCATTCCGTCAGGATTCAA R: CTGGTCTTCATTCTCATCTTC
MIR4435-2HG	F: TGATAAAGGGCTCTGAAAGC R: CACGATGCCTTCACCAGTGT

AC245100.7 F: GGAATATGGATGACTGGTTATC
R: AGGAGGAGGAATAATATGACAG

AL137782.1 F: TGAAGAACGAGCCAGATAC
R: CCTGAGATACAGCCAACC

GAPDH F: TCGGAGTCAACGGATTTGGTCGT
R: TGCCATGGGTGGAATCATATTGGA

Supplementary Table 4 The Necroptosis-related long noncoding RNAs significantly correlated with overall survival according to univariate Cox and multivariate Cox regression analyses.

Uni-Cox					Multi-Cox				
ID	HR	HR. 95L	HR. 95H	<i>p</i> valu e	Coef	HR	HR. 95L	HR. 95H	<i>p</i> valu e
AC008	2.15	1.40	3.32	0.00					
760.1	70	13	03	05					
AC007	1.53	1.11	2.10	0.00					
038.2	15	23	87	90					
AC073	1.44	1.04	2.01	0.02					
957.3	99	57	03	59					
AP001	1.67	1.04	2.67	0.03	0.39	1.48	0.88	2.48	0.13
469.3	13	50	31	21	55	52	79	42	18
AC079	1.51	1.06	2.16	0.02					
684.1	34	01	06	25					
AL161	1.58	1.13	2.20	0.00					
729.4	01	44	08	68					
LINC0	1.50	1.03	2.18	0.03					
1876	46	76	19	12					
AC092	1.39	1.06	1.82	0.01					
535.4	15	40	00	58					

SNHG	0.59	0.36	0.96	0.03						
16	64	90	38	48						
AL354	1.48	1.04	2.10	0.02						
993.2	44	66	52	67						
AC007	1.59	1.01	2.51	0.04	0.49	1.64	0.97	2.78	0.06	
128.1	87	59	58	25	98	84	59	43	17	
AC011	1.79	1.16	2.75	0.00						
462.4	01	16	88	83						
AC016	1.41	1.01	1.98	0.04						
394.1	54	15	06	27						
AC048	1.55	1.11	2.17	0.00						
341.2	81	69	34	90						
AP006	1.45	1.11	1.90	0.00						
621.2	35	05	23	65						
LINC0	1.61	1.10	2.38	0.01	0.39	1.47	0.93	2.33	0.09	
2381	88	06	11	44	03	75	40	72	53	
LINC0	2.33	1.37	3.95	0.00						
1138	14	48	35	17						
AC099	0.74	0.55	0.99	0.04	-0.29	0.74	0.53	1.04	0.08	
850.3	70	94	77	82	19	68	60	06	45	
AC010	2.28	1.43	3.64	0.00	0.77	2.17	1.30	3.62	0.00	
973.2	48	07	89	05	57	21	00	95	31	
AC018	1.46	1.01	2.11	0.04						
653.3	39	42	30	18						
AC087	1.59	1.01	2.50	0.04						
741.1	61	75	37	18						
AC084	1.77	1.08	2.89	0.02						
033.3	17	37	64	26						
LENG8	1.54	1.10	2.15	0.01						
-AS1	15	40	24	11						

MIR44	1.76	1.10	2.82	0.01	0.74	2.10	1.19	3.73	0.01
35-2H	62	33	75	78	66	98	16	57	04
G									
ZKSC	1.71	1.16	2.51	0.00					
AN2-D	60	89	91	58					
T									
AC245	2.08	1.39	3.10	0.00	0.47	1.60	1.04	2.45	0.03
100.7	40	67	96	03	13	21	56	48	04
AP001	1.42	1.02	1.99	0.03					
628.1	61	16	09	70					
AC078	1.51	1.08	2.11	0.01					
778.1	37	09	98	58					
AL137	0.38	0.17	0.83	0.01	-1.12	0.32	0.15	0.68	0.00
782.1	38	65	46	57	65	42	27	80	33

HR: Hazard ratio; multi-Cox: Multivariate Cox analysis; uni-Cox: Univariate Cox analysis.

Supplementary Table 5 The Gene Set Enrichment Analysis results showing the top ten enriched Kyoto Encyclopedia of Genes and Genomes and Gene Ontology terms in the high-risk patient group.

Name	Si ze	ES	NE S	NOM p-val ue	FDR q-val ue	Ran k at max	Leading edge
KEGG_VA							
SCULAR_							Tags = 42%,
SMOOTH	11	0.5	2.0	0.004	0.067	7694	list = 14%,
_MUSCLE	5	47	57				signal =
_CONTRA							48%
CTION							
KEGG_NE	27	0.5	1.9	0.002	0.186	1468	Tags = 53%,
UROACTI	1	13	10			3	list = 27%,

VE_LIGA							signal =
ND_RECE							72%
PTOR_INT							
ERACTIO							
N							
KEGG_GL							
YCOSAMI							
NOGLYC							Tags = 68%,
AN_BIOS	22	0.6	1.8	0.012	0.180	1188	list = 22%,
YNTHESIS		95	69			5	signal =
_CHOND							87%
ROITIN_S							
ULFATE							
KEGG_BA							Tags = 40%,
SAL_CELL	55	0.5	1.8	0.016	0.161	9724	list = 18%,
_CARCIN		18	50				signal =
OMA							48%
KEGG_CA							Tags = 44%,
LCIUM_SI	17	0.4	1.8	0.006	0.171	1057	list = 19%,
GNALING	7	68	15			2	signal =
_PATHW							54%
AY							
KEGG_CO							
MPLEME							Tags = 43%,
NT_AND_	69	0.5	1.8	0.010	0.150	1114	list = 20%,
COAGUL		66	09			3	signal =
ATION_C							54%
ASCADES							
KEGG_HY							Tags = 53%,
PERTROP	83	0.5	1.7	0.012	0.141	1153	list = 21%,
HIC_CAR		17	98			2	signal =

DIOMYOP							67%
ATHY_HC							
M							
KEGG_DI							Tags = 52%,
LATED_C	90	0.5	1.7	0.010	0.131	1153	list = 21%,
ARDIOMY		22	90			2	signal =
OPATHY							66%
KEGG_EC							Tags = 56%,
M_RECEP	84	0.6	1.7	0.030	0.123	8928	list = 16%,
TOR_INTE		30	84				signal =
RACTION							67%
KEGG_FO							Tags = 41%,
CAL_ADH	19	0.5	1.7	0.046	0.171	9013	list = 16%,
ESION	9	07	23				signal =
							49%
GOBP_M							Tags = 49%,
USCLE_O	31	0.5	2.3	0.000	0.085	1097	list = 20%,
RGAN_DE	4	57	06			9	signal =
VELOPME							60%
NT							
GOBP_RE							
GULATIO							
N_OF_CA							Tags = 48%,
LCIUM_I	14	0.5	2.2	0.000	0.207	1081	list = 20%,
ON_TRA	2	44	02			7	signal =
NSMEMB							59%
RANE_TR							
ANSPORT							
GOBP_RE							Tags = 53%,
GULATIO	75	0.6	2.2	0.000	0.183	1061	list = 19%,
N_OF_RE		00	02			6	signal =

LEASE_OF							66%
_SEQUENT							
ERED_CA							
LCIUM_I							
ON_INTRO							
_CYTOSO							
L							
GOMF_IO							Tags = 46%,
N_CHAN	11	0.5	2.1			1153	list = 21%,
NEL_REG	6	24	94	0.000	0.155	2	signal =
ULATOR_							58%
ACTIVITY							
GOBP_VIS							Tags = 46%,
UAL_BEH	46	0.5	2.1	0.000	0.139	9720	list = 18%,
AVIOR		95	87				signal =
							55%
GOBP_RE							
GULATIO							
N_OF_CA							Tags = 55%,
LCIUM_I	94	0.5	2.1	0.000	0.116	1061	list = 19%,
ON_TRA		96	87			6	signal =
NSPORT_I							68%
NTO_CYT							
OSOL							
GOCC_CO							
LLAGEN_							Tags = 51%,
CONTAIN	42	0.6	2.1			1051	list = 19%,
ING_EXT	0	11	77	0.002	0.114	1	signal =
RACELLU							63%
LAR_MAT							
RIX							

GOCC_CI							Tags = 57%,
LIARY_TI	44	0.6	2.1	0.000	0.103	8259	list = 15%,
P		87	74				signal =
							67%
GOBP_RE							
GULATIO							Tags = 40%,
N_OF_PO	98	0.5	2.1	0.000	0.092	7877	list = 14%,
TASSIUM		41	73				signal =
_ION_TR							46%
ANSPORT							
GOBP_NE							
GATIVE_							
REGULAT							
ION_OF_T							Tags = 30%,
RANSCRI	20	0.6	2.1	0.000	0.083	5956	list = 11%,
PTION_RE		67	73				signal =
GULATO							34%
RY_REGI							
ON_DNA							
_BINDING							

Supplementary Table 6 The infiltrated immune cells in the tumor microenvironment were associated with the high-risk group on different platforms

Immune cells	<i>p</i> value
T cell CD4+_TIMER	0.025575699
Macrophage_TIMER	0.005425421
T cell CD4+ memory activated_CIBERSORT	0.022840768
Macrophage M2_CIBERSORT	0.020015435
Mast cell resting_CIBERSORT	0.011851149
T cell CD4+ memory	0.036437142

activated_CIBERSORT-ABS	
Macrophage M0_CIBERSORT-ABS	0.015820259
Macrophage M2_CIBERSORT-ABS	0.028552775
Endothelial cell_MCPCOUNTER	0.0341941
Cancer associated fibroblast_MCPCOUNTER	0.000326605
B cell_XCELL	0.0354134
T cell CD4+ memory_XCELL	0.003397362
T cell CD8+ central memory_XCELL	0.001022351
Class-switched memory B cell_XCELL	0.002424344
Hematopoietic stem cell_XCELL	1.53E-05
T cell NK_XCELL	0.00718224
Plasmacytoid dendritic cell_XCELL	0.004593612
B cell plasma_XCELL	0.001617021
T cell CD4+ Th2_XCELL	0.005936061
T cell regulatory (Tregs)_XCELL	0.01809725
stroma score_XCELL	0.045599495
Cancer associated fibroblast_EPIC	0.000205684
uncharacterized cell_EPIC	0.003073026
